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TO BIOPRINT OR NOT TO BIOPRINT 
Jasper L. Tran* 
Recent scholarship on regulating 3D printing implicitly 
presumes the same regulation should apply to printing from both 
non-biological materials and biological materials. However, this 
presumption is mistakenly grounded. Technically, bioprinting is a 
subcategory of 3D printing. However, printing from biological 
materials presents different public policy considerations than 
printing from non-biological materials. When experimenting with 
mammalian genetic materials, emerging technological and scientific 
advances attract strong political, regulatory, and ethical debates. 
The societal scrutiny is further heightened when the genetic 
materials are from humans. 
One analyst group speculates a global debate in 2016 as to 
whether to regulate bioprinting or ban it altogether. Banning 
bioprinting altogether is an easy solution, but it will stop technology 
and science from progressing. The more difficult question is how the 
law should regulate bioprinting. Current regulations on synthetic 
biology are not sufficiently comprehensive to regulate bioprinting 
because bioprinting moves synthetic biology’s production out of the 
laboratory and into everyone’s home. After analyzing different ways 
to regulate bioprinting, this Article offers a novel framework to 
regulate bioprinting: except for research and life-threatening 
emergency, the legislature and the medical profession should jointly 
regulate access to bioprinting’s blueprints, sources, and bioprinters.  
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I. INTRODUCTION  
“Everything you can imagine is real.” 
—Pablo Picasso 
For example, Australian researchers recently were able to 3D-
print brain tissue.1 Five decades ago, Star Trek introduced the 
Replicator concept—a machine that can create anything out of thin 
air.2 Who would have thought such a sci-fi myth could be real?3 
Well, it is—the 3D printer is a modern day Replicator.4 3D printers 
are technically not “new”—engineers have been using them since 
the 1980s. 5  Nonetheless, 3D printers are finally available for 
                                                
1 Rodrigo Lorezno et al., 3D Printing of Layered Brain-Like Structures Using 
Peptide Modified Gellan Gum Substrates, 67 BIOMATERIALS 264, 264–73 
(2015) (demonstrating “a novel process to create a 3D brain-like structure 
consisting of layered primary cortical cells encapsulated in hydrogels 
representing cortical tissue”). 
 2 In Star Trek, the Replicators originally synthesized meals on demand, but 
took on other uses in the later series. See Star Trek: The Original Series (NBC 
television broadcast Sept. 8, 1966–June 3, 1969) (referring to “food 
synthesizer”); Star Trek: The Next Generation (NBC television broadcast Sept. 
28, 1987–May 23, 1994); Star Trek: Enterprise (NBC television broadcast 
September 26, 2001–May 13, 2005) (referring to “protein resequencer” and 
“bio-matter resequencer”). 
 3 See CHRIS ANDERSON, MAKERS: THE NEW INDUSTRIAL REVOLUTION 8–9, 
58–59 (2012); (stating that the first wave of “geeks” are “rushing to explore this 
strange new world” of 3D printing which is “quickly becoming a mainstream 
phenomenon.”); James Bruce, 3D Printing – Sci-Fi Myth Or Reality?, 
MAKEUSEOF (Aug. 31, 2011), http://www.makeuseof.com/tag/3d-printing-scifi-
myth-reality/; Clive Thompson, We Need a Fixer (Not Just a Maker) Movement, 
WIRED (June 18, 2013, 6:30 AM), http://www.wired.com/2013/06/qq_thompson; 
see also Grey’s Anatomy: Two Against One (ABC television broadcast Nov. 8, 
2013) (showing medical staff fighting over their 3D printer to build new 
lifesaving organs). 
 4 Deven R. Desai, The New Steam: On Digitization, Decentralization, and 
Disruption, 65 HASTING L.J. 1469, 1471 (2014) [hereinafter Desai, New Steam]. 
For background information on 3D printing, see generally discussion infra Part 
II.A. 
 5  Melissa A. Barnett, The Next Big Fight: 3D Printing and Intellectual 
Property, LEXOLOGY (Jan. 31, 2014), http://www.lexology.com/ 
library/detail.aspx?g=2fdd3f59-3a6a-4066-9ded-56501a8aaa45. 
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purchase.6 With time, 3D printers will get “cheaper, faster, and 
more mainstream.”7 Soon, 3D printers will be just another home 
appliance,8 and unsurprisingly, people will forget about how the 
3D printer was once science fiction.9 
By the same token, people mistakenly have the same 
skepticism about bioprinting.10 Yet, Dr. Anthony Atala11 recently 
gave two TED talks, 12 Growing New Organs 13 and Printing a 
                                                
 6  See, e.g., 3D Printers, STAPLES, http://www.staples.com/3D-
Printers/cat_CL211598 (last visited Oct. 23, 2014); see also Price Compare – 
3D Printers, 3DERS, http://www.3ders.org/pricecompare/3dprinters/ (last visited 
Oct. 23, 2014) (comparing prices of 3D printers). 
 7 Alex Hern, 3D Printers Get Cheaper, Faster - and More Mainstream, THE 
GUARDIAN (Sept. 24, 2013 12:59 PM), http://www.theguardian.com/ 
technology/2013/sep/24/3d-printers-get-cheaper-faster-and-more-mainstream. 
 8 Steven Kurutz, A Factory on Your Kitchen Counter, N.Y. TIMES (Feb. 20, 
2013), http://www.nytimes.com/2013/02/21/garden/the-3-d-printer-may-be-the-
home-appliance-of-the-future.html?pagewanted=all; see also Mark A. Lemley, 
IP in a World Without Scarcity, 90 N.Y.U. L. REV. 460, 474–75 [hereinafter 
Lemley, IP Without Scarcity] (anticipating a time where the general public will 
have ready access to 3D printers). 
 9 Some examples of common-place technological advancements that people 
once considered science fiction are robots, robotic body parts (arms, legs), 
spray-on skin and most recently, self-driving vehicles. 
 10 Bioprinting is also referred to as 3D Bioprinting. For a discussion on 
bioprinting, see generally discussion infra Part II.C. Note that bioprinting does 
not refer to “DNA bioprints,” which is “a simplified DNA nonisotopic 
fingerprinting system using biotin-labeled probes.” See, e.g., Sérgio D.J. Pena et 
al., DNA Bioprints: Simple Ponisotopic DNA Fingerprints with Biotinylated 
Probes, 12 ELECTROPHORESIS 146, 146–52 (1991). 
 11 Dr. Anthony Atala is a practicing surgeon and the director of the Wake 
Forest Institute for Regenerative Medicine. Anthony Atala, TED, 
http://www.ted.com/speakers/anthony_atala (last visited Oct. 23, 2014) (“[Our 
lab uses] a desktop inkjet printer, but instead of using ink, we’re using cells.”). 
 12 See Our Organization, TED, http://www.ted.com/about/our-organization 
(last visited Oct. 23, 2014) (“TED is a nonprofit devoted to spreading ideas, 
usually in the form of short, powerful talks (18 minutes or less).”) 
 13  Anthony Atala: Growing New Organs, TED (Oct. 2009) 
http://www.ted.com/talks/anthony_atala_growing_organs_engineering_tissue 
(presenting that instead of harvesting or transplanting human organs, Anthony 
Atala’s lab grows human organs—from muscles to blood vessels to bladders, 
and more) [hereinafter TED talk: Growing New Organs]. 
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Human Kidney, 14  presenting that the emerging field of 
bioprinting—printing mammalian or human body parts15—is also 
real and bioprinters will soon be widely available.16 Scientists 
made bioprinting possible 17  by marrying the concepts of 3D 
printing and synthetic biology.18 
We live in a digitization age.19 Computers and the Internet 
digitize information.20 While 3D printing digitizes tangible goods,21 
bioprinting digitizes human body parts22 and, potentially, human 
                                                
 14  Anthony Atala: Printing a Human Kidney, TED (Mar. 2011), 
http://www.ted.com/talks/anthony_atala_printing_a_human_kidney [hereinafter 
TED talk: Printing Human Kidney] (demonstrating a 3D printer using living 
cells to output a transplantable kidney). 
 15 See discussion infra Part II.C. 
 16 Bioprinters are already available for research purposes. See, e.g., Daniel J. 
Thomas, Technology to Bioprint Tissues on Demand in 3D is Here, 3DERS 
(Sept. 21, 2014), http://www.3ders.org/articles/20140921-technology-to-
bioprint-tissues-on-demand-in-3d-is-here.html [hereinafter 3DERS: Bioprint 
Tissues on Demand]; Alec, ‘3D Bioprinting Solutions’ to Reveal First Russian 
3D Bioprinter in Late October, 3DERS (Sept. 25, 2014), 
http://www.3ders.org/articles/20140925-russian-company-3d-bioprinting-
solutions-to-reveal-their-bioprinter.html, [hereinafter 3DERS: Russian 3D 
Printer]. 
 17 See discussion infra Part II.C. 
 18 Synthetic biology aims to design an organism from scratch or modify an 
existing organism for useful purposes. See generally discussion infra Part II.B 
and notes 172–174 and accompanying text. 
 19 Devan R. Desai & Gerald N. Magliocca, Patents, Meet Napster: 3D 
Printing and the Digitization of Things, 102 GEO. L.J. 1691, 1692 (2014) 
[hereinafter Desai & Magliocca, Napster]; Desai, New Steam, supra note 4, at 
1469. “Digitization” (or “digitalization”) means the process of converting 
information into a digital format. See MERRIAM WEBSTER’S COLLEGIATE 
DICTIONARY (10th ed. 1998). 
 20 See Lemley, IP Without Scarcity, supra note 8, at 469–71. 
 21 Desai & Magliocca, Napster, supra note 19, at 1692; see also Lucas S. 
Osborn, Of PhDs, Pirates and the Public: Three-Dimensional Printing 
Technology and the Arts, 1 TEX. A&M L. REV. 811, 819–23 (2014) [hereinafter 
Osborn, 3D Printing & Arts] (discussing 3D printing’s digitization of everyday 
things and ancient arts). 
 22 Cf. TED talk: Growing New Organs, supra note 13 (presenting that instead 
of harvesting human organs, Anthony Atala’s lab grows human organs such as 
muscles, blood vessels, bladders, and more). 
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beings.23 Although digitization offers many benefits, it also brings 
challenges,24 which disrupt both business25 and law.26 
Recent scholarship on regulating 3D printing implicitly 
presumes the same regulations should apply to printing from both 
non-biological materials and biological materials.27 However, this 
presumption is mistaken. For example, an individual recently 
diagnosed with lung cancer could simply print another compatible 
lung from her home bioprinter and have a doctor replace her 
current lung with this new lung.28 It would be ridiculous to regulate 
a 3D-printed lung the same way as a common household item, for 
example, a 3D-printed fork. Although bioprinting is a subcategory 
of 3D printing, 29  printing from biological materials presents 
different public policy considerations than printing from non-
biological materials. 30  When experimenting with mammalian 
genetic materials, as scientists did in the past with the cloning of 
                                                
 23 Osborn, 3D Printing & Arts, supra note 21, at 815–19. 
 24 Desai & Magliocca, Napster, supra note 19, at 1692. 
 25 See, e.g., Lemley, IP Without Scarcity, supra note 8, at 474 (“A world in 
which sophisticated 3D printers are widely available would change the 
economics of things in a fundamental way . . .”). 
 26  E.g., Lucas S. Osborn, Regulating Three-Dimensional Printing: The 
Converging Worlds of Bits and Atoms, 51 SAN DIEGO L. REV. 553, 562–92 
(2014) [hereinafter Osborn, Regulating 3D Printing] (discussing that 3D 
printing raises legal issues in intellectual property law, environmental law, 
contract law, products liability, criminal law, and firearms control). See 
generally discussion, infra Part III.A and notes 161–166 and accompanying text. 
 27 See, e.g., Jasper L. Tran, 3D Printing and the Law, 31 J. INFO. TECH. & 
PRIVACY L. 505 (2015); Desai & Magliocca, Napster, supra note 19, at 1703–
20; Osborn, Regulating 3D Printing, supra note 26, at 562–92. But see Lemley, 
IP Without Scarcity, supra note 8, at 472–79 (distinguishing 3D printing and 
bioprinting). 
 28 This assumes that such bioprinter can easily load this individual’s biological 
information to print a compatible lung. 
 29 See discussion, infra Parts II.A. and II.C. 
 30  For a discussion on the ethical, legal and policy issues behind 
commercializing genetic research, see generally THE COMMERCIALIZATION OF 
GENETIC RESEARCH: ETHICAL, LEGAL, AND POLICY ISSUES (Timothy A. 
Caulfield & Bryn Williams-Jones eds., 1999). 
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Dolly, 31  emerging technological and scientific advances attract 
strong political, regulatory, and ethical debates.32 When the genetic 
materials are from humans, such as during human stem cell 
research,33 the societal scrutiny is further heightened.34 
                                                
 31 Dolly (July 5, 1996–Feb. 14, 2002) was the first mammal (sheep) cloned 
from an adult somatic cell using nuclear transfer. For a discussion on cloning 
and Dolly, see generally Anne McLaren, Cloning: Pathways to a Pluripotent 
Future, 288 SCIENCE 1775–80 (2000); Ian Wilmut et al., Viable Offspring 
Derived from Fetal and Adult Mammalian Cells, 385 NATURE 810–13 (1997). 
 32 See, e.g., Lori B. Andrews, Is There A Right to Clone? Constitutional 
Challenges to Bans on Human Cloning, 11 HARV. J.L. & TECH. 643 (1998) 
[hereinafter Andrews, Right to Clone?]; Katheryn D. Katz, The Clonal Child: 
Procreative Liberty and Asexual Reproduction, 8 ALB. L.J. SCI. & TECH. 1 
(1997) [hereinafter Katz, Clonal Child]; John A. Robertson, Liberty, Identity, 
and Human Cloning, 76 TEX. L. REV. 1371 (1998) [hereinafter Robertson, 
Human Cloning]; Janet A. Warrington, The Ethics of Reproductive Cloning, 19 
SANTA CLARA COMPUTER & HIGH TECH. L.J. 471 (2003) [hereinafter 
Warrington, Reproductive Cloning]. 
 33 Stem cell research dates back to the 1960s. See Andy J. Becker et al., 
Cytological Demonstration of the Clonal Nature of Spleen Colonies Derived 
from Transplanted Mouse Marrow Cells, 197 NATURE 452–54 (1963). Stem 
cells are undifferentiated cells that can divide and differentiate into specialized 
cells. For a discussion on stem cells, see generally Bernard E. Tuch, Stem 
Cells—A Clinical Update, 35 AUSTRALIAN FAM. PHYSICIAN 719–21 (2006) 
[hereinafter Tuch, Stem Cells]. 
 34 See, e.g., Leili Fatehi & Ralph F. Hall, Symposium, Enforcing the Rights of 
Human Sources to Informed Consent and Disclosures of Incidental Findings 
from Biobanks and Researchers: State Mechanisms in Light of Broad 
Regulatory Failure, 13 MINN. J.L. SCI. & TECH. 575 (2012) [hereinafter Fatehi 
& Hall]; Heather Johnson Kukla, Note, Embryonic Stem Cell Research: An 
Ethical Justification, 90 GEO. L.J. 503 (2002) [hereinafter Kukla, Ethical 
Justification]; William McGeveran et al., Deidentification and Reidentification 
in Returning Individual Findings from Biobank and Secondary Research: 
Regulatory Challenges and Models for Management, 13 MINN. J.L. SCI. & 
TECH. 485 (2012) [hereinafter McGeveran, Biobank]; Radhika Rao, Coercion, 
Commercialization, and Commodification: The Ethics of Compensation for Egg 
Donors in Stem Cell Research, 21 BERKELEY TECH. L.J. 1055 (2006) 
[hereinafter Rao, Ethics of Compensation]; David E. Winickoff et. al., Opening 
Stem Cell Research and Development: A Policy Proposal for the Management 
of Data, Intellectual Property, and Ethics, 9 YALE J. HEALTH POL’Y, L. & 
ETHICS 52 (2009) [hereinafter Winickoff, Policy Proposal]. See generally Henry 
T. Greely, Symposium, The Control of Genetic Research: Involving the 	
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Research involving the use of bioprinted products inside and 
outside the human body triggers different ethical concerns.35 To 
illustrate, using bioprinted products inside a human body may 
trigger biosafety concerns and violate human dignity. Other ethical 
concerns include the questionable sources of the biomaterials as 
well as how to eliminate their “waste.” Although most of these 
ethical concerns are not unique to bioprinting, regulating 
bioprinting will likely differ from regulating 3D printing. 
One analyst group speculates a global debate in 2016 regarding 
whether to regulate bioprinting or ban it altogether.36 Banning 
bioprinting altogether 37  is an easy solution, but it will stop 
technology and science from progressing.38 The more challenging 
solution would allow bioprinting, which would raise the difficult 
question how the law should regulate the technology. Current 
regulations on synthetic biology 39  are not sufficiently 
comprehensive to regulate bioprinting because bioprinting moves 
synthetic biology’s production out of the laboratory and into the 
home.40 Currently, what regulation the bioprinting technology must 
abide by still leaves a big question mark—a “grey” area—because 
                                                                                                         
“Groups Between,” 33 HOUS. L. REV. 1397 (1997) (discussing the control of 
human genetic research). 
 35 See discussion, infra Part III.A. 
 36 Press Release, The Gartner Group, Gartner Says Uses of 3D Printing Will 
Ignite Major Debate on Ethics and Regulation (Jan. 29, 2014), available at 
http://www.gartner.com/newsroom/id/2658315 (“Rapid development of 3D 
bioprinters will spark calls to ban the technology for human and nonhuman use 
by 2016”). For a discussion on the bioprinting market, see generally ROOT 
ANALYSIS PRIV. LTD., 3D BIOPRINTING MARKET, 2014 - 2030 (2014). 
 37 See The Gartner Group, supra note 36. This statement presumes no research 
exception. For a discussion of the research exception, see discussion, infra Part 
IV.A.2. 
 38 This question presumes that 3D printing will not be banned altogether. For 
a discussion of an outright ban on bioprinting, see discussion, infra Part IV.A.1. 
 39 See e.g., Andrew W. Torrance, Symposium, Synthesizing Law for Synthetic 
Biology, 11 MINN. J.L. SCI. & TECH. 629 (2010) (analyzing the legal regime 
behind synthetic biology); see also discussion, infra Part III.B.2. 
 40 Cf. Kurutz, supra note 8 (discussing that 3D printer will soon be just 
another home appliance). See generally discussion, infra Part II.B (comparing 
bioprinting to synthetic biology). 
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bioprinting regulation could fall under human stem cell research 
regulation for bioprinting ink, organ transplantation regulation for 
bioprinted organs, or both.41 After analyzing different ways to 
regulate bioprinting, this Article offers a novel framework to 
regulate bioprinting: except for research and life-threatening 
emergencies, the legislature and the medical profession should 
jointly regulate access to bioprinting’s blueprints, sources, and 
bioprinters.42 
This Article proceeds in five parts. Part II provides the 
scientific facts and current regulation on 3D printing, synthetic 
biology and bioprinting. Part III analyzes and synthesizes the 
rationales for regulating bioprinting by comparing it to 3D 
printing, synthetic biology, stem cell research, organ 
transplantation, and cloning. Part IV explores different ways to 
regulate bioprinting. Part V proposes regulating bioprinting 
through joint efforts of the legislature and the medical profession 
to maximize bioprinting’s advantages while also considering the 
rationale behind bioprinting. Part V further addresses the 
proposal’s advantages and implications, and then rebuts some of 
the common counterarguments against this proposal. Part VI 
concludes. 
II. BIOPRINTING: THE STEPCHILD OF 3D PRINTING AND 
SYNTHETIC BIOLOGY 
To understand bioprinting, it is only natural to first introduce 
its parents: 3D printing and synthetic biology. This Part provides 
scientific facts on 3D printing in Section A, synthetic biology in 
Section B, and bioprinting in Section C. Three-dimensional 
printing stacks multiple layers of two-dimensional printing on top 
of one another. Synthetic biology synthesizes DNA artificially to 
replicate organisms. Bioprinting, in short, is the three-dimensional 
printing of synthetic biological organs. 
                                                
 41 See discussion, infra Part III.D. 
 42 See discussion, infra Part V.A. 
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A. The Mother of Bioprinting: 3D Printing 
Michelangelo carved statues by “hew[ing] away the rough 
walls that imprison the lovely apparition to reveal it to the other 
eyes as [his] see it.”43 3D printing accomplishes the opposite—it 
transforms manufacturing.44 3D printers45 add another dimension to 
our current (2D) printers.46 Rather than printing ink, 3D printers 
print three-dimensional objects.47 3D printers print by setting raw 
materials into two-dimensional patterns on a platform and 
gradually raising to stack each layer on top of the next until 
completion.48 Current 3D printers can print in materials like plastic, 
                                                
 43  Saad Shaikh & James Leonard-Amodeo, The Deviating Eyes of 
Michelangelo’s David, 98 J. ROYAL SOC. MED. 75, 75 (2005) (quoting 
Michelangelo) (“In every block of marble I see a statue as plain as though it 
stood before me, shaped and perfect in attitude and action. I have only to hew 
away the rough walls that imprison the lovely apparition to reveal it to the other 
eyes as mine see it.”). 
 44 Desai & Magliocca, Napster, supra note 19, at 1719. 
 45 3D printing modalities include extrusion, photolithography, and 
stereolithography. For the latest news on 3D printing, see 3DERS, 
http://www.3ders.org (last visited Oct. 23, 2014) (providing latest news and 
developments of 3D printing technology and 3D printers). 
 46  For a discussion on the history of printing, see generally WARREN 
CHAPPELL & ROBERT BRINGHURST, A SHORT HISTORY OF THE PRINTED WORD 
(2000) (covering history of printing from the earliest alphabets, through the 
evolution of the printing press, the contributions of great printers and 
typographers, and twentieth century graphic technology). 
 47 E.g., HOD LIPSON & MELBA KURMAN, FABRICATED: THE NEW WORLD OF 
3D PRINTING 68–84 (2013); Osborn, 3D Printing & Arts, supra note 21, at 813. 
(“3D ‘printers’ are only superficially related to current 2D printers. Rather than 
printing ‘ink,’ they ‘print’ (expel) solid or molten material. Further, they print 
not just in two dimensions, but also move in a third direction: the printer head 
moves up (or the base moves down) to stack layer upon layer of expelled 
material until a three-dimensional object is formed.”). 
 48 Desai & Magliocca, Napster, supra note 19, at 1695–96. Although 3D 
printing theoretically includes printing by subtraction (rather than just addition), 
this Article only focuses on 3D additive printing. Desai & Magliocca note that 
3D printing by subtraction raises many of the same legal issues as additive 3D 
printing. Id. at 1692 n.1. For a discussion on 3D printer by subtraction (such as 
milling machine), see generally Tom Owad, When Less Is More: The Takeaway 
on Milling vs. 3D Fabrication, MAKE, Winter 2013, at 10, 11. 
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metal, ceramic, cement, wood, food, and human cells.49 Like the 
“Star Trek Replicator”,50 3D printers can print anything, from a 
lithium-ion microbattery51 to a bionic ear.52 
To print an object, 3D printers need an electronic blueprint to 
follow—a Computer-Aided Design file (“CAD file”).53 Users can 
create CAD files by designing from scratch or scanning an object.54 
Like Microsoft Word documents, photographs and music, users 
can edit and share CAD files with others through the Internet.55 
3D printing is still in its infancy, but its potential is 
significant. 56  The introduction of 3D printing completely 
revolutionizes the world of tangible goods,57 from manufacturing58 
                                                
 49 LIPSON & KURMAN, supra note 47, at 68–75; Osborn, 3D Printing & Arts, 
supra note 21, at 813–14. 3D printing that prints in human cells is called 
“bioprinting.” For a discussion on bioprinting, see discussion, infra Part II.C. 
 50 See discussion, supra Part I and note 2. 
 51  Ke Sun et al., 3D Printing of Interdigitated Li-Ion Microbattery 
Architectures, 25 ADVANCED MATERIALS 4539, 4539–43 (2013). A 
microbattery is sized at a grain of sand. Id. 
 52 Manu Mannoor et al., 3D Printed Bionic Ears, NANO LETTERS (2013), 
http://www.princeton.edu/~nverma/VermaLabSite/Publications/2013/MannoorJia
ngJamesKongMalatestaSoboyejoVermaGraciasMcAlpine_NanoLetters2013.pdf 
[hereinafter Mannoor, Bionic Ears]. 
 53 Osborn, 3D Printing & Arts, supra note 21, at 814. This is unsurprising 
given that 2D printers also need an electronic blueprint to print—a Microsoft 
Word document or the like. 
 54  Id. (“Various Computer-Aided Design (‘CAD’) programs (Google 
Sketchup, AutoCAD, etc.) allow users to design and modify three-dimensional 
objects on a computer.”).  
 55 Id. at 814–15. 
 56 Lemley, IP Without Scarcity, supra note 8, at 471 (“3D printing is in its 
infancy as a technology, but already the potential for transformation is clear”). 
 57 See Richard A. D’Aveni, 3-D Printing Will Change the World, HARV. BUS. 
REV. (Mar. 2013), http://hbr.org/2013/03/3-d-printing-will-change-the-world/. 
 58 See Barack Obama, Remarks by the President in the State of the Union 
Address (Feb. 12, 2013), http://www.whitehouse.gov/the-press-
office/2013/02/12/remarks-president-state-union-address (“3D printing . . . has 
the potential to revolutionize the way we make almost everything”); Desai & 
Magliocca, Napster, supra note 19, at 1695 (“3D printing reorders access to the 
means of production”). 
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to art 59  or even healthcare. 60  3D printing eliminates cost of 
distribution and substantially reduces cost of manufacturing.61 
B. The Father of Bioprinting: Synthetic Biology 
Synthetic biology is relatively young compared to 3D 
printing.62 The interdisciplinary field63 of synthetic biology64 builds 
on genetic engineering65 to design an organism from scratch66 or 
modify an existing organism for useful purposes. 67  Recent 
synthetic biology advances include synthesizing DNA artificially 
(i.e., creating DNA parts), 68  creating novel replicating 
                                                
 59 Osborn, 3D Printing & Arts, supra note 21, at 815–17. 
 60 Kathryn Doyle, 3 Ways 3-D Printing Could Revolutionize Healthcare, 
FORBES (Aug. 22, 2013), http://www.forbes.com/sites/xerox/2013/08/22/3-
ways-3-d-printing-could-revolutionize-healthcare/ [hereinafter Doyle, 
Revolutionize] (discussing that 3D printing could revolutionize healthcare 
through scaffolding, medical devices and human tissues). See generally 
discussion on Bioprinting, infra Part II.C. 
 61 Lemley, IP Without Scarcity, supra note 8, at 474–75. 
 62 Id. at 479 (“[s]ynthetic biology is at an earlier stage than 3D printing”). 
 63 The interdisciplinary field of synthetic biology combines disciplines such as 
biotechnology, evolutionary biology, molecular biology, systems biology, and 
biophysics. Synthetic biology builds on genetic engineering. 
 64 Synthetic biology’s definition has been heavily debated among people in 
natural sciences, human sciences, arts, and politics. This Article adopts the 
definition based on synthetic biology’s functional aspect, stemming from 
molecular biology and biotechnology. 
 65 Drew Andy, Foundations for Engineering Biology, 438 NATURE 449, 449–
53 (2005) (describing the considerable promise and limitations of synthetic 
biology). 
 66 In May 2010, Craig Venter’s group created the first synthetic genome of a 
bacterium Mycoplasma mycoides at a cost of over $40 million. See Press 
Release, J. CRAIG VENTER INST., First Self-Replicating Synthetic Bacterial Cell 
(May 20, 2010), http://www.jcvi.org/cms/press/press-releases/full-
text/article/first-self-replicating-synthetic-bacterial-cell-constructed-by-j-craig-
venter-institute-researcher/home/. 
 67 Mark A. J. Roberts et al., Synthetic Biology: Biology by Design, 159 
MICROBIOLOGY 1219, 1219–1220 (2013) (holding synthetic biology is defined 
as “design and construct[ion] [of] novel biologically based parts, devices and 
systems, [and] redesign[ing] existing natural biological systems, for useful 
purposes”). 
 68 Id. 
136 N.C. J.L. & TECH. [VOL. 17: 123 
microorganisms, 69  and using microbes as biofactories 70  or as 
biological computers.71 Even the U.S. Supreme Court has taken 
interest in synthetic biology, allowing the patenting of disease-
resistance crops, 72  “new” organisms, 73  and shorter DNA 
sequences74 as long as they are not naturally occurring.75 
Synthetic biology builds on gene assemblers 76  by linking 
together four natural nucleotides (A, C, G, T) 77  into a new, 
synthetic strand of genetic material.78 Recently, synthetic biologists 
even created two new, synthetic nucleotides (X, Y).79 Currently, 
                                                
 69 See, e.g., Daniel G. Gibson et al., Creation of a Bacterial Cell Controlled by 
a Chemically Synthesized Genome, 329 SCIENCE 52, 52–56 (2010). 
 70 See Jerome Bonnet et al., Rewritable Digital Data Storage in Live Cells via 
Engineered Control of Recombination Directionality, 109 PROC. NAT’L ACAD. 
SCI. U.S. 8884, 8884–89 (2012). 
 71  See Paul Oldham et al., Synthetic Biology: Mapping the Scientific 
Landscape, 7 PLOS ONE e34368, e34368 (2012). 
 72  See, e.g., Bowman v. Monsanto, 133 S. Ct. 1761, 1761–69 (2013) 
(adjudicating dispute over patent on genetically-modified soybean seeds). 
 73 See Diamond v. Chakrabarty, 447 U.S. 303, 303–18 (1980) (adjudicating 
dispute over patent on oil-eating bacteria). 
 74 See Ass’n for Molecular Pathology v. Myriad, 133 S. Ct. 2107, 2107–20 
(2013) (adjudicating dispute over patents on two breast cancer susceptibility 
genes). 
 75 Lemley, IP Without Scarcity, supra note 8, at 475–79; see also 35 U.S.C. 
§ 101 (2012) (excluding product[s] of nature from patentable subject matters). 
 76 See, e.g., Monya Baker, De Novo Gene Assembly: What Every Biologist 
Should Know, 9 NATURE METHODS 333, 333–37 (2012). 
 77 Nucleotides are base pairs for DNA and RNA that make up all genetic 
materials: As pair with Ts, and Cs pair with Gs. For background information on 
nucleotides, see generally BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF 
THE CELL 120–21 (4th ed. 2002). 
 78 Lemley, IP Without Scarcity, supra note 8, at 477. 
 79 Andrew Pollack, Scientists Add Letters to DNA’s Alphabet, Raising Hope 
and Fear, N.Y. TIMES, May 7, 2014. (needs a page cite or weblink) See 
generally Denis A. Malyshev et al., A Semi-Synthetic Organism with an 
Expanded Genetic Alphabet, 509 NATURE 385, 385–88 (2014) (discussing the 
successful insertion of X-Y base pair into the common bacterium E. coli, which 
subsequently reproduced normally, replicating the X and Y along with the 
natural nucleotides). 
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synthetic biologists are developing “BioBricks”80—biological parts 
consisting of individual DNA modules assembled together to 
construct organisms.81 
In this model, genes become both computers and builders.82 
The possibilities are limitless—“the ability to manipulate 
organisms to do anything imaginable may lead to new products 
that are currently unimaginable.”83 For example, synthetic biology 
may allow for obtaining “cheap, organic, self-constructing 
housing” from genetically modified plants that grow into a 
building,84 or ordering custom genes at the doctor’s office.85 
C. The Birth of Bioprinting 
Combining 3D printing’s mechanics86 and synthetic biology’s 
raw materials87 results in bioprinting.88 Using BioBricks as the 
basic building blocks, 3D printers can print a mammalian or 
human body part (altogether as bioprinting’s “products”).89 Like 
                                                
 80 For a discussion on Biobrick, see generally Reshma P Shetty et al., 
Engineering BioBrick Vectors from BioBrick Parts, 2 J. BIOLOGICAL 
ENGINEERING 1, 1–12 (2008). As of 2008, there were already over 2,000 
BioBricks available from the Registry of Standard Biological Parts. Id. Note that 
Biobrick is different from Biosimilar, a type of pharmaceutical drug. For a 
discussion of biosimilar, see generally Vinita Banthia, Note, Biosimilar 
Regulation: Bringing the United States Up to Speed with Other Markets, 16 
MINN. J.L. SCI. & TECH. 879, 879–916 (2015). 
 81 Lemley, IP Without Scarcity, supra note 8, at 476. 
 82 Id. at 476–77. 
 83 Id. at 479. 
 84 Id. at 477; see Tom McKeag, Will Synthetic Biology Lead to Truly Living 
Buildings?, GREENBIZ (June 16, 2010), http://www.greenbiz.com/blog/ 
2010/06/16/will-synthetic-biology-lead-truly-living-buildings. 
 85 Lemley, IP Without Scarcity, supra note 8, at 479. 
 86 See discussion, supra Part II.A. 
 87 See discussion, supra Part II.B. 
 88  See Ken Doyle, Bioprinting: From Patches to Parts, 34 GENETIC 
ENGINEERING & BIOTECHNOLOGY NEWS 1, 1 [hereinafter Doyle, From Patches 
to Parts]. Bioprinting modalities include photolithography, magnetic 
bioprinting, stereolithography, and direct cell extrusion. See Piyush Bajaj et al., 
3D Biofabrication Strategies for Tissue Engineering and Regenerative 
Medicine, 16 ANN. REV. BIOMEDICAL ENGINEERING 247, 247–76 (2014). 
 89 See Doyle, From Patches to Parts, supra note 88 at 1. 
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synthetic biology, bioprinting has a wide range of uses: anything 
from repairing90 and replacing91 broken body parts to adding newly 
engineered tissues.92 
Readers might ask—how is this possible? 3D printing’s 
precision and synthetic biology’s sterilization technique convert 
the sci-fi myth of creating mammalian or human body parts into 
reality.93 Bioprinting only requires a 3D printer, a blueprint to 
follow (so the bioprinter knows exactly what it needs to print), and 
human cells as raw materials (similar to ink in the 2D printer).94 As 
Dr. Anthony Atala 95  puts it: we can grow organs instead of 
transplanting them. 96  Beyond bioprinting body parts, some 
speculate future possibilities of printing mammalian or human 
clones (“cloneprinting”),97 and bringing back extinct animals.98 
                                                
 90 See Xiaofeng Cui et al., Direct Human Cartilage Repair Using Three-
Dimensional Bioprinting Technology, 18 TISSUE ENGINEERING PART A 1304, 
1304–12 (2012). 
 91 See Sean V. Murphy & Anthony Atala, 3D Bioprinting of Tissues and 
Organs, 32 NATURE BIOTECHNOLOGY 773, 773–85 (2014) [hereinafter Murphy 
& Atala] (discussing how surgeons can transplant bioprinted organs). 
 92  See, e.g., Stefanie Michael et al., Tissue Engineered Skin Substitutes 
Created by Laser-Assisted Bioprinting Form Skin-Like Structures in the Dorsal 
Skin Fold Chamber in Mice, 8 PLOS ONE e57741, e57741 (2013). 
 93 See discussion, supra Parts II.A and II.B. 
 94 See generally Jasper L. Tran, Patenting Bioprinting, HARV. J.L. & TECH. 
DIGEST (2015), http://jolt.law.harvard.edu/digest/patent/patenting-bioprinting 
[hereinafter Tran, Patenting Bioprinting]. 
 95 See Atala, supra  note 11. 
 96 TED talk: Growing New Organs, supra note 13. Technically, bioprinting 
prints organs, but does not “grow” organs. 
 97 Thomas Frey, How Long Before I Can 3D Print a Replacement Body for 
Myself?, FUTURISTSPEAKER (May 22, 2014), http://www.futuristspeaker.com/ 
2014/05/how-long-before-i-can-3d-print-a-replacement-body-for-myself/; 
Patrick J. Lynch, Is Bioprinting the Pathway to Human Cloning?, SCIENCE 
QUICK PICKS (Feb. 29, 2012), http://pontotriplo.org/quickpicks/is-bioprinting-
pathway-human-cloning.html [hereinafter Lynch, Bioprinting the Pathway to 
Cloning]; see, e.g., Dann Albright, How 3D Printing Humans Might Be Possible 
Some Day, MAKEUSEOF (Oct. 23, 2014), http://www.makeuseof.com/tag/3d-
printing-humans-might-possible-day/. For a discussion on cloneprinting, see 
generally discussion, infra Part III.A.5. 
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Bioprinting is at an even earlier stage of development than 3D 
printing or synthetic biology.99 Early commercial applications of 
bioprinting will likely be drug testing 100  and skin grafting. 101 
Although bioprinters are currently available,102 bioprinting is still a 
future technology.103 Compared to 3D printing, “there is still a long 
way to go before [bioprinting] becomes affordable, available, and 
commercially interesting.”104 
There are currently no regulations on bioprinting.105 Similarly, 
there has also been no litigation on bioprinting, and none is 
expected anytime soon.106 In 2014, the United States Patent and 
Trademark Office (“USPTO”)107 published the first two patent 
applications 108  on bioprinting, 109  assigned to an “early-stage 
                                                                                                         
 98 See, e.g., JURASSIC PARK (Universal Pictures, Amblin Entertainment 1993) 
(bringing back dinosaurs); cf. THE FIFTH ELEMENT (Gaumont 1997) (recreating 
a perfect being from a DNA block). But see, e.g., Andy Roast, De-Extinction: 
Mammoth Prospect, or just Woolly?, BBC NEWS (Aug. 20, 2013), 
http://www.bbc.com/news/science-environment-23602142 (“[N]o-one is 
seriously considering bringing back dinosaurs . . . .”). 
 99 See discussion supra Parts II.A and II.B. 
 100 ROOT ANALYSIS, supra note 36, at 10. 
 101 See Lin Edwards, Printed Cells to Treat Burn Victims, PHYS.ORG (Apr. 12, 
2010), http://phys.org/news190269898.html. 
 102 See, e.g., 3DERS: Bioprint Tissues on Demand, supra note 16; 3DERS: 
Russian 3D Printer, supra note 16. 
 103 Cf. Lemley, IP Without Scarcity, supra note 8, at 479 (“I don’t expect to be 
printing my own organisms any time soon.”). 
 104 3DERS: Russian 3D Printer, supra note 16. 
 105 See Mathew Varkey & Anthony Atala, Organ Bioprinting: A Closer Look 
at Ethics and Policies, 5 WAKE FOREST J.L. & POL’Y 275, 284–86 (2015); 
Michael H. Park, Note, For A New Heart, Just Click Print: The Effect on 
Medical and Products Liability from 3-D Printed Organs, 2015 U. ILL. J.L. 
TECH. & POL’Y 187, 191–97 (2015). 
 106 Cf. Lemley, IP Without Scarcity, supra note 8. 
 107  See generally About Us, USPTO, http://www.uspto.gov/about-us (last 
visited Oct. 27, 2014) (“USPTO is the federal agency for granting U.S. patents 
and registering trademarks.”). 
 108 See 35 U.S.C. § 122 (2012) (“[E]ach application for a patent shall be 
published . . . promptly after the expiration of a period of 18 months from the 
earliest filing date for which a benefit is sought under this title.”). See generally 
35 U.S.C. § 282(b)(2) (2012) (presuming granted patents are valid until 
challenged). 
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regenerative medicine” company named Organovo. 110  In fact, 
Organovo was the first company/entity to commercialize 
bioprinting,111 with plans to test toxicity on its 3D liver model in 
December of 2014.112 The Organovo bioprinter can print skin 
tissue, heart tissue, blood vessels, and other basic tissues for 
surgical therapy and transplantation.113 
III. RATIONALES BEHIND REGULATING BIOPRINTING 
To come up with the rationale for regulating the newly 
emerging field of bioprinting, it is helpful to look at and synthesize 
from the rationales of similar existing technologies. This Part 
analyzes and synthesizes the rationales for regulating bioprinting 
by comparing it to 3D printing, synthetic biology, stem cell 
research, organ transplantation, and cloning. Section A examines 
some possible bioprinting ethical arguments. Section B compares 
bioprinting to these technologies. Section B concludes that from 
the least to highest required regulatory scrutiny, the order for these 
technologies is: (1) 3D printing, (2) synthetic biology, 
(3) bioprinting, (4) stem cell research, and (5) organ 
transplantation.114 Section C further synthesizes public policy to 
begin thinking about bioprinting regulation. Section D discusses 
the current regulatory framework that bioprinting would abide by. 
                                                                                                         
 109 See, e.g., U.S. Patent Publication No. 20140093932 A1 (filed Mar. 11, 
2013) (Murphy et al., applicants); U.S. Patent Publication No. US20140012407 
A1 (filed Mar. 11, 2013). See generally Bioprint Patents, FRESHPATENTS, 
http://tgs.freshpatents.com/Bioprint-bx1.php (last visited Oct. 27, 2014) 
(updating published bioprinting patents and patent applications). 
 110  See generally About Organovo, ORGANOVO, 
http://www.organovo.com/company/about-organovo (last visited Nov. 1, 2014) 
(“[Organovo] design[s] and create[s] functional human tissues using our 
proprietary three-dimensional bioprinting technology.”). For a thorough 
discussion on patenting bioprinting, see Tran, Patenting Bioprinting, supra note 
94. 
 111 See Doyle, From Patches to Parts, supra note 88. 
 112 ROOT ANALYSIS, supra note 36, at 10. 
 113 Murphy & Atala, supra note 91, at 773–85. 
 114 See discussion, infra Part III.B.  
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A. Bioprinting Ethics 
Although there are many ways to analyze bioprinting ethics, 
this Article applies four ethical frameworks to examine some 
bioprinting ethical arguments.115 Note that this is not the only way 
to analyze bioprinting ethics. Although this section does not cover 
all the possible ethical arguments regarding bioprinting, it serves as 
a starting point to a discussion of bioprinting ethics.116 
1. Intrinsic 
Research involving bioprinted products used inside and outside 
a human body trigger different ethical concerns. For example, 
using bioprinted products inside a human body may implicate 
biosafety concerns and raise issues over whether human dignity 
has been violated. 117  Other ethical concerns include the 
questionable sources of the biomaterials as well as how to 
eliminate their waste.118 
Some of the concerns with bioprinting come from a religious 
perspective in which technologies that alter a biological state are 
viewed as a violation of religious principles.119 
Others may be concerned about the sources of stem cells used 
in bioprinting ink, because some stem cells are derived from the 
                                                
 115 Cf. J. Burkhardt, What can Nano Learn from Bio? Presentation at the 
Institute of Food and Agricultural Sciences Conference on Nanotechnology 
(2005) (applying four ethical frameworks to nanotechnology). 
 116 This kind of ethical framework was initially adopted from biological 
science to nanotechnology. Given that bioprinting combines (synthetic) biology 
and computer science (3D printing), this framework makes the most sense. 
 117 See Varkey & Atala, supra note 105, at 284. 
 118 Cf. Sibel Tunali Akar et al., Biosorption Potential of the Waste Biomaterial 
Obtained from Cucumis melo for the Removal of Pb2+ Ions from Aqueous 
Media: Equilibrium, Kinetic, Thermodynamic and Mechanism Analysis, 185–86 
CHEMICAL ENGINEERING J. 82, 82 – 90 (2012). 
 119 See Christian Brugger, Printers Aren’t Just For Homework Anymore: The 
Science and Ethics of Bioprinting, CULTURE OF LIFE FOUND (Sept. 9, 2013), 
http://www.culture-of-life.org/2013/09/10/pr-intersarent-just-homework-
anymore-science-and-ethics-bioprinting/; see also John Zingarelli, Is 
“Creation” A Religious Concept?, 8 REGENT U. L. REV. 35, 39 (1997) 
(discussing God and “natural” matters). 
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destruction of human embryos. 120 For those who view human 
embryos as human beings, killing embryos would be wrong, even 
if doing so can save human life.121 
Environmentalists may be concerned about the possibility of 
bioprinters emitting unhealthy air and contributing to 
environmental pollution.122 The public generally might worry about 
the safety of bioprinted products, especially when used in a human 
body, e.g., issues like malfunction incidents, and who should bear 
liability for such incidents? A government branch most familiar 
with health and human services, as suggested later in this Article, 
would be fully capable to handle these safety issues.123 
2. Consequential 
For the cosmetic industry, there might be a similar problem to 
that of “designer babies”124: “athletes and people seeking body 
modification for personal satisfaction or to gain an edge for 
themselves.”125 It does not seem unreasonable to presume that 
“individuals will try to find ways to enhance themselves with 3D 
printing if they can get an advantage,” 126  given that “[s]ome 
athletes already assume significant risks to increase their 
performance on the field using illegal substances with serious side 
                                                
 120 See Brugger, supra note 119. 
 121 See Bonnie Steinbock, The Morality of Killing Human Embryos, 34 J.L. 
MED & ETHICS 26, 32–34 (2006). 
 122 See Lyndsey Gilpin, The dark side of 3D printing: 10 things to watch, 
TECHREPUBLIC (Mar. 5, 2014 4:51 AM), http://www.techrepublic.com/article/ 
the-dark-side-of-3d-printing-10-things-to-watch/. For a study on 3D printing’s 
emission, see generally Brent Stephens, et al., Ultrafine particle emissions from 
desktop 3D printers, 79 ATMOSPHERIC ENVIRONMENT 334, 334–39 (2013) 
(discussing that bioprinters using PLA filament emitted 20 billion ultrafine 
particles/minute, and the ABS emitted up to 200 billion particles/minute for 
heating plastic and printing small figures). 
 123 See discussion infra Part V.A. 
 124  See Sonia M. Suter, A Brave New World of Designer Babies?, 22 
BERKELEY TECH. L.J. 897, 929–34 (2007). 
 125  Richard Adhikari, Bioprinting, Part 2 - The Ethical Conundrum, 
TECHNEWSWORLD (Mar. 27, 2014 6:30 AM PT), 
http://www.technewsworld.com/story/80205.html. 
 126 Id. 
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effects, . . . [and o]thers might seek enhancements to help achieve 
their ideal of beauty.”127 
Subsequently, if enhanced bioprinted body parts are desirable, 
a black market may emerge.128 An extreme example might be that 
having a hand with six functional fingers could be viewed as 
“better” than having one with five functional fingers. Furthermore, 
if one is “desperate and [has expired health insurance] and need[s] 
a new [body part], [s/he would] go to the black market stalls.”129 
But more problems arise when an individual buys a defective body 
part or receives a transplant from a black-market surgeon—for 
example, whom to sue when there arise surgical complications or 
infection.130 
3.  Right/Consent Base 
Traditional human rights activists may argue that bioprinting 
violates human dignity and integrity.131 However, human dignity is 
increasingly used as a “form of general condemnation and as 
blanket justification for regulatory restraint,” and “on its own, [is 
a] dubious justification for policies that are aimed at constraining 
controversial biotechnologies.”132  
Assuming brain transplantation is possible, some express 
concern that brain transplantation using bioprinted brains would 
risk losing that individual’s identity and personality by memory 
loss, character, psychological development, and brain-body 
history.133 The counterargument would be that bioprinting solves 
                                                
 127 Id. 
 128 See MICHELE GOODWIN, BLACK MARKETS: THE SUPPLY AND DEMAND OF 
BODY PARTS 170–71 (2013) [hereinafter GOODWIN, BODY PARTS BLACK 
MARKETS] (discussing the black market for organs). 
 129 Hop Lipson & Melba Kurman, Navigating the Ethical Minefield of Bio-
Printing, BIGTHINK, http://bigthink.com/in-their-own-words/navigating-the-
ethical-minefield-of-bio-printing (last visited Dec. 15, 2014). 
 130 Id. 
 131 See Timothy Caulfield & Roger Brownsword, Human Dignity: A Guide to 
Policy Making in the Biotechnology Era?, 7 NATURE REV. GENETICS 72, 72–76 
(2006). 
 132 Id. at 72. 
 133 See id. 
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the current organ shortage in organ transplantation,134 for which the 
benefits might outweigh the potential risks/harms.135 
Moreover, another argument is that patients for new or 
experimental treatments often serve as guinea pigs.”136 Although 
most people would have a choice whether they would use a 
bioprinted product, some people, especially those on the organ 
transplantation waitlist, are desperate. 137  This form of 
experimentation can be viewed as coercion—desperate terminal 
patients have no choice but to accept an experimental bioprinted 
organ.138 
4.  Structural/Procedural  
Some economists might argue, “[j]ust because something 
works in the lab doesn’t mean it will work in the marketplace, 
especially with the cost of healthcare.”139 Accordingly, the United 
States might be better off economically by investing in healthcare 
resources elsewhere. 140  However, the counterargument is that 
bioprinting might actually preserve more healthcare resources in 
the long run.141 For example, instead of continuously fixing an 
organ over and over again, it might make more sense to replace 
that organ. 
Bioprinting could create an inequality between different 
countries because bioprinting could advance unabated in countries 
with less-restrictive government oversight, whereas clinical trials 
and testing of organs for transplantation in the United States could 
                                                
 134 See discussion infra Part V.B.2. 
 135 See discussion infra Part III.C.3. 
 136 Adhikari, supra note 125. 
 137 See id. 
 138 Cf. Leonard W. Schroeter, Human Experimentation, the Hanford Nuclear 
Site, and Judgment at Nuremberg, 31 GONZ. L. REV. 147, 153 (1995–96) 
(discussing human experimentation as coercion). 
 139 Adhikari, supra note 125 (quoting Charlie Whelan, Healthcare and Life 
Science Director of Consulting at Frost & Sullivan). 
 140 See Dan W. Brock & Daniel Wikler, Ethical Issues in Resource Allocation, 
Research, and New Product Development, in DISEASE CONTROL PRIORITIES IN 
DEVELOPING COUNTRIES 259 (Dean T. Jamison et al. eds., 2d ed. 2006). 
 141 See discussion infra Part V.B.2. 
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take up to a decade given the Food and Drug Administration’s 
(“FDA”) 142  stringent reviews. 143  The United States already has 
guidelines to handle patients being exposed to new medical 
technologies. For example, “[t]he FDA has strict safety and 
efficacy standards for implants made from a patient’s own cells,”144 
and “[h]ospital oversight boards would regulate donor issues, cells 
and tissue for informed consent.”145 The United States, which has 
been known as a world leader in technology,146 might fall behind at 
its own game when it comes to bioprinting. 147  Furthermore, 
bioprinting’s “ability to build customized human anatomical parts 
has pervasive appeal in medical device markets especially in 
economically weak and war-torn regions where it addresses high 
demand for prosthetic and other medical devices.” 148  Another 
concern is that large population regions with inadequate access to 
                                                
 142 For background on the FDA, see generally About FDA: What We Do, 
FDA, http://www.fda.gov/AboutFDA/WhatWeDo/default.htm (last visited Nov. 
4, 2014). 
 143  See Lucas Mearian, Bio-Printing Human Parts will Spark Ethical, 
Regulatory Debate: 3D Printing also Threatens Intellectual Property Rights, 
COMPUTER WORLD (Jan. 29, 2014 6:33 AM PT), 
http://www.computerworld.com/article/2486998/emerging-technology/bio-
printing-human-parts-will-spark-ethical--regulatory-debate.html?page=2. 
 144 Adhikari, supra note 125 (quoting Jordan Miller, Assistant Professor of 
Bioengineering at Rice University). 
 145 Id. (citing Kevin E. Healy, Chair of the Bioengineering Department at 
University of California, Berkeley). 
 146 See, e.g., U.S. Remains the Dominant Leader in Science and Technology 
Worldwide, HOMELAND SECURITY NEWS WIRE (June 15, 2008), 
http://www.homelandsecuritynewswire.com/us-remains-dominant-leader-
science-and-technology-worldwide. 
 147 See also Kevin G. Coleman, US Moving From Technology Leader To 
Laggard, INFORMATIONWEEK (Dec. 2, 2013 2:15 PM), 
http://www.informationweek.com/government/cybersecurity/us-moving-from-
technology-leader-to-laggard-/d/d-id/1112861 (discussing how the U.S. is 
lagging in research and development (R&D), science, and technology 
investments). 
 148 Mearian, supra note 143. 
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emerging healthcare technology, such as China or India,149 could 
face inequality issues. 
Additionally, some bioprinted products could become cheaper 
and more accessible but other products like functioning hearts, 
which could be extremely complex to bioprint, would “likely be 
only accessible to those willing to pay for personalized 
treatments.”150 If some new bioprinted products are more expensive 
than existing treatments, healthcare would likely not cover such 
cost, and thus, only the rich would be able to afford them.151 
Consequently, the division between the rich and the poor would 
grow larger.152 
B. Comparing to Existing Regulations 
After analyzing bioprinting ethics, it seems as though the ethics 
of bioprinting are not unique to bioprinting itself, but have 
surfaced before in existing technologies, such as 3D printing, 
synthetic biology, stem cell research, organ transplantation and 
cloning.153 Therefore, it makes sense to compare bioprinting with 
the listed technologies to determine where bioprinting falls on the 
ethical spectrum. In doing so, this Article explains the rationales 
behind each technology’s regulation, whether such regulatory 
approach’s results are “good” or “bad,” and what and how 
bioprinting regulation can learn from the listed technologies. This 
Article also provides the current regulations on those existing 
technologies as a starting point to think about regulating 
bioprinting. 
                                                
 149 See, e.g., Yarlini Balarajan et al., Health Care and Equity in India, 377 
LANCET 505, 505–15 (2011) (India). 
 150 Adhikari, supra note 125 (quoting Kirstin Matthews, Fellow in Science 
and Technology Policy at Rice University’s Baker Institute). 
 151 See id. 
 152 See id. (“This will continue to expand the access divide between the haves 
and the have nots.”). 
 153 Some of these ethical issues are discussed in detail later. See discussion 
infra Part V.C. 
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1.  Much Higher Scrutiny than 3D Printing 
As previously mentioned,154 recent scholarship on regulating 
3D printing 155  implicitly presumes the same regulation should 
apply both to bioprinting and 3D printing. Technically, bioprinting 
is a subcategory of 3D printing.156 3D printing can print both non-
biological and biological matters.157 However, non-biological items 
e.g., a pencil, are ready to use, whereas bioprinting’s products, 
such as an ear 158  or a lung, require surgeons and doctors’ 
assistance. 
Further, printing from biological materials presents different 
public policy considerations than printing from non-biological 
materials. Compared to non-biological materials, experimenting 
with mammalian genetic matter generates strong political, 
regulatory and ethical debates.159 The societal scrutiny heightens 
when the genetic materials are from humans. 160  Because 
bioprinting involves the use of mammalian and human genetic 
materials, bioprinting will be subject to much higher scrutiny than 
3D printing. 
                                                
 154 See discussion supra Part I. 
 155 See, e.g., Desai & Magliocca, Napster, supra note 19, at 1703–20; Osborn, 
Regulating 3D Printing, supra note 26, at 562–92. 
 156 See discussion supra Parts II.A and II.C (discussing that bioprinting is a 
type of 3D printing that prints from BioBricks). 
 157 See discussion supra Part II.A. 
 158 See Adam Shaw, Growing an Ear: How 3D Bio Printing Could Change 
the World, BRIT. AIRWAYS: BUS. LIFE (June 5, 2013), 
http://businesslife.ba.com/Ideas/Features/Growing-an-ear-how-3D-bio-printing-
could-change-the-world.html (Cornell scientists “are not just printing life—like 
copies of ears—they are actually producing real ears, made of human tissue, that 
function as normal ears and could be transplanted on to humans.”); cf. Mannoor, 
Bionic Ears, supra note 52 (discussing 3D printing bionic ears). 
 159 See, e.g., Andrews, Right to Clone?, supra note 32; Katz, The Clonal 
Child, supra note 32; Robertson, Human Cloning, supra note 32; Warrington, 
Reproductive Cloning, supra note 32. 
 160 See, e.g., Fatehi & Hall, supra note 34; Kukla, Ethical Justification, supra 
note 34; McGeveran, Biobank, supra note 34; Rao, Ethics of Compensation, 
supra note 34; Winickoff, Policy Proposal, supra note 34. 
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Unfortunately, 3D printing has already faced many legal 
challenges 161  in intellectual property (IP) law, 162  environmental 
law, 163  contract law, 164  products liability, 165  criminal law, and 
firearms control.166 3D-printing-related litigation is emerging and 
robust, especially in the patent infringement context.167 One analyst 
                                                
 161 Osborn, Regulating 3D Printing, supra note 26, at 562–92; Desai & 
Magliocca, Napster, supra note 19, at 1692. 
 162 Osborn, Regulating 3D Printing, supra note 26, at 582–92; Daniel Harris 
Brean, Asserting Patents to Combat Infringement via 3D Printing: It’s No 
“Use”, 23 FORDHAM INTELL. PROP., MEDIA & ENT. L.J. 771 (2012); Davis 
Doherty, Note, Downloading Infringement: Patent Law as a Roadblock to the 
3d Printing Revolution, 26 HARV. J.L. & TECH. 353 (2012) (outlining possible 
patent infringement scenarios and culpable infringers arising from consumer use 
of 3D printers). But see Joseph C. Storch, 3-D Printing Your Way Down the 
Garden Path: 3-D Printers, the Copyrightization of Patents, and a Method for 
Manufacturers to Avoid the Entertainment Industry’s Fate, 3 N.Y.U. J. INTELL. 
PROP. & ENTM’T L 249, 309 (2014) (proposing that “manufacturers should not 
engage in a litigation strategy of suing individual consumers or a legislative 
strategy of seeking to increase fines or criminal penalties for such violations[, 
but instead,] acknowledge their loss of a technical monopoly, and the 
concomitant loss of legal monopoly protection that practically accompanies such 
a paradigm shift”). 
 163 Osborn, Regulating 3D Printing, supra note 26, at 564–66 (3D printing 
reduces waste but could emit toxic fumes). 
 164 Id. at 571–72 (raising questions like whether CAD files are “goods,” 
whether CAD file sellers are “merchants,” and sale vs. license). 
 165 Id. at 566–71 (raising questions like whether CAD files are “products,” 
who to sue for “selling” or “otherwise distributing” such products, and whether 
strict liability should apply to “manufacturing” defect). 
 166 Id. at 576–82. Recently, Sen. Charles Schumer (D-NY) and Sen. Bill 
Nelson (D-FL) have introduced legislation to expand the undetectable firearms 
law to ban 3D-printed guns. See Press Release, Sen. Charles E. Schumer, U.S. 
Sen. for N.Y., Schumer, Nelson Call for Revamping, Extending Reagan-Era 
Firearms Act that Bans New Practice of Creating Undetectable Guns, at Home, 
with 3-D Printer, BILLNELSON.SENATE.GOV (June 13, 2013), 
http://www.billnelson.senate.gov/newsroom/press-releases/schumer-nelson-call-
for-revamping-extending-reagan-era-firearms-act-that (last visited Sept. 4, 
2015). 
 167 See, e.g., 3D Sys., Inc. v. Formlabs, Inc., No. 13-cv-7973, 2014 WL 
1904365 (S.D.N.Y. May 12, 2014) (patent infringement); Barranco v. 3D Sys. 
Corp., No. 13-cv-00412, 2014 WL 1091740 (D. Haw. Mar. 17, 2014) 
(contractual claims); Stratasys, Inc. v. Microboards Tech., LLC, No. CIV. 13-	
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group even predicts an annual global IP loss of at least $100 billion 
from 3D printing by 2018.168 
2.  Slightly Higher Scrutiny Than Synthetic Biology 
Bioprinting stems from synthetic biology. 169  However, 
bioprinting differs in that bioprinting moves synthetic biology’s 
production out of the laboratory to everyone’s home.170 Although 
both bioprinting and synthetic biology still require doctors’ 
assistance,171 bioprinting is more accessible than synthetic biology. 
Therefore, bioprinting deserves slightly higher scrutiny than 
synthetic biology. 
Legally, synthetic biology is subject to the same bioethics and 
biosecurity issues as recombinant DNA and genetically modified 
organisms because these processes all utilize the same source—
biological materials.172 Except for the regulation of DNA synthesis 
companies, 173  synthetic biology presumably follows existing 
                                                                                                         
3228 DWF/TNL, 2015 WL 1608344 (D. Minn. Apr. 10, 2015); 3D Sys., Inc. v. 
Formlabs & Kickstarter, No. 12-cv-03323 (D. S.C.) (patent infringement—
pending settlement);, 3D Sys., Inc. v. EnvisionTec, Inc., No. 05-74891, 2011 
WL 4691937 (E.D. Mich. Oct. 6, 2011) (patent infringement—ended in a 
settlement shortly after the district court’s infringement ruling); see also, e.g., 
Doherty, supra note 162 (outlining possible patent infringement scenarios and 
culpable infringers arising from consumer use of 3D printers). For a discussion 
on patent litigation, see generally Jasper L. Tran, Timing Matters: Prior Art’s 
Age Infers Patent Nonobviousness, 50 GONZ. L. REV. 189 (2015); Jasper L. 
Tran, Software Patents: A One-Year Review of Alice v. CLS Banks, 97 J. PAT. & 
TRADEMARK OFF. SOC’Y 532 (2015). 
 168  Gartner: 3D Printing to Result in $100 Billion IP Losses per Year, 
3DERS.ORG (Oct. 14, 2013) [hereinafter $100 Billion IP Losses], 
http://www.3ders.org/articles/20131014-gartner-3d-printing-to-result-in-100-
billion-ip-losses-per-year.html. (last visited Sept. 4, 2015). 
 169 See discussion, supra Parts II.B. and II.C. 
 170 Cf. Kurutz, supra note 8 (discussing that 3D printer will soon be just 
another home appliance). 
 171 See discussion, supra Parts II.B. and II.C. 
 172 See Hans Bügl et al., DNA Synthesis and Biological Security, 25 NATURE 
BIOTECHNOLOGY 627, 627–29 (2007). 
 173 See id. 
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regulations of genetic engineering and pathogen research. 174 
Following this line of logic, some might argue that bioprinting 
would likely fall under the same regulation regime.175 
3. Slightly Less Scrutiny Than Stem Cell Research 
What bioprinting and stem cell research have in common is 
that they both involve using genetic materials from mammals, 
including humans.176 However, the source of the genetic materials 
differs. Stem cell researchers harvest stem cells from mammalian 
newborns, 177  whereas bioprinting takes advantage of synthetic 
biology’s technology178 and uses synthetic BioBricks,179 which are 
created in a laboratory. 180  Because synthesizing new genetic 
materials is likely more humane and acceptable than harvesting 
genetic material from existing living mammals and humans, 
bioprinting will be subject to slightly less scrutiny than stem cell 
research. 
Until recently, the U.S. banned stem cell research and thus, 
made no scientific progression in the field of stem cell research. In 
2009, U.S. President Barack Obama issued an Executive Order 
                                                
 174 PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL ISSUES, NEW 
DIRECTIONS: THE ETHICS OF SYNTHETIC BIOLOGY AND EMERGING 
TECHNOLOGIES 36, 56–72 (2010), available at 
http://permanent.access.gpo.gov/gpo9019/PCSBI-Synthetic-Biology-Report-
12.16.10.pdf (recommending no changes to policy or oversight and calling for 
continued funding of the research and new funding for monitoring, study of 
emerging ethical issues, and public education). But, over 100 environmental and 
civil society groups advocate for a worldwide ban on the release and commercial 
use of synthetic organisms and the use of synthetic biology in human genome or 
human microbiome until more robust regulations and rigorous biosafety 
measures are established. See FRIENDS OF THE EARTH ET AL., THE PRINCIPLES 
FOR THE OVERSIGHT OF SYNTHETIC BIOLOGY (2012),) available at 
http://www.synbioproject.org/site/assets/files/1270/principles_for_the_oversight
_of_synthetic_biology.pdf. 
 175 But see discussion, infra Parts IV and V (discussing how regulating 
bioprinting would likely be more complicated). 
 176 See discussion, supra Part II.C and note 33. 
 177 See Tuch, Stem Cells, supra note 33. 
 178 See discussion, supra Parts II.B. and II.C. 
 179 See discussion, supra Part II.B and notes 80–81. 
 180 See discussion, supra Part II.C. 
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titled “Removing Barriers to Responsible Scientific Research 
Involving Human Stem Cells” to remove the ban and allow further 
research using stem cells.181 Current human stem cell research still 
must adhere to the National Institute of Health’s (“NIH” 182 ) 
guidelines.183 Furthermore, other federal regulations govern various 
aspects of Human Embryonic Stem Cell Research, including: 
Human subjects protection for donors of somatic cells and oocytes and 
for some donors of embryos. Medical privacy protections. Laboratory 
standards for investigators whose work will result in products that 
require Food and Drug Administration (FDA) approval. Safety reviews 
of laboratory work that involves genetic alteration of [human stem] cell 
lines. Animal care committee reviews of [human stem] cell research 
that uses nonhuman animals. Various rules governing the importation 
of biological materials or the transfer of medical data from other 
countries. 184 
In short, stem cell research is regulated one way or another. 
4. Much Less Scrutiny Than Organ Transplantation 
Although both bioprinting and organ transplantation185 involve 
human genetic materials, they do not draw from the same source. 
With the exception of kidneys, each individual has only one of 
                                                
 181 Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009); see also Bill 
Mears, Supreme Court Allows Federal Stem Cell Research to Continue, CNN 
(Jan. 8, 2013, 12:28 PM EST), http://www.cnn.com/2013/01/07/justice/stem-
cell-appeal/ (“Supreme Court . . . dismissed a long-standing appeal from 
scientists who tried to block funding of stem cell research on human embryos.”). 
 182  See generally About NIH, NAT’L INST. OF HEALTH, 
http://www.nih.gov/about/ (last visited Dec. 16, 2014). 
 183  See National Institutes of Health Guidelines on Human Stem Cell 
Research, NAT’L INST. OF HEALTH (July 7, 2009), http://stemcells.nih.gov/p 
olicy/pages/2009guidelines.aspx (last visited Dec. 16, 2014); see also Draft 
National Institutes of Health Guidelines for Human Stem Cell Research Notice, 
74 Fed. Reg. 18,578-01 (Apr. 23, 2009) (discussing drafted guidelines for 
human stem cell research). 
 184 GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH 63 (Nation 
Resource Council and Institute of Medicine) (2005), available at 
http://www.nap.edu/catalog/11278/guidelines-for-human-embryonic-stem-cell-
research. 
 185 The term “organ transplantation” used throughout this Article includes 
both organ harvesting and transplantation. 
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each organ needed to live,186 creating a worldwide shortage of 
available organs187 for organ transplantation, which “mandates the 
need to guard the ethical standard of medical priorities for those 
patients that depend on the transplantation to save their lives.”188 
Thus, organ transplantation regulations are universally extensive, 
complex, and extremely strict.189 Conversely, bioprinting creates 
organs from scratch.190 
While organ failure might occur in both bioprinting and organ 
transplantation191 bioprinting body parts from an individual’s own 
genetic materials avoids the problem of transplant rejection, 192 
even though such body parts from bioprinting might still 
malfunction. In a way, bioprinting revolutionizes organ 
transplantation193 and should not be subject to the extremely high 
level of scrutiny currently used for organ transplantation; instead, 
bioprinting should be subject to a lower level of scrutiny. 
Current regulation of organ transplantation in the U.S. falls 
under the National Organ Transplantation Act (NOTA) of 1984, 
                                                
 186 Each individual has 2 kidneys, but only needs one to live. 
 187  Rafael Beyar, Challenges in Organ Transplantation, 2 RAMBAM 
MAIMONIDES MED. J. e0049(1), e0049(2) (2011); See also Rachel Johnson et al., 
Kidney Donation and Transplantation in the UK from 1998 to 2007, CLINICAL 
TRANSPLANTATION 75, 75–88 (2008). 
 188  Rafael Beyar, Challenges in Organ Transplantation, 2 RAMBAM 
MAIMONIDES MED. J. e0049(1), e0049(2) (2011). 
 189  See, e.g., UNITED NETWORK FOR ORGAN SHARING, TALKING ABOUT 
TRANSPLANTATION: WHAT EVERY PATIENT NEEDS TO KNOW 3–27 (2013) 
available at http://www.unos.org/docs/WEPNTK.pdf. 
 190 See, e.g., TED talk: Growing New Organs, supra note 13. See generally 
discussion, supra Part II.C. 
 191 See Christopher J. E. Watson & John H. Dark, Organ Transplantation: 
Historical Perspective and Current Practice, 108 BRITISH J. ANESTHESIA i29, 
i29–42 (2012) (discussing organ failure by transplantation). 
 192 Transplant rejection occurs when the transplanted recipient’s immune 
system rejects and destroys the transplanted tissue. For a discussion on 
transplant rejection, see generally Christoph Frohn et al., The Effect of HLA-C 
Matching on Acute Renal Transplant Rejection, 16 NEPHROLOGY DIALYSIS 
TRANSPLANTATION 355, 355–60 (2001). 
 193 Cf. Doyle, Revolutionize, supra note 60 (discussing that 3D printing could 
revolutionize healthcare through human tissues). 
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which establishes the framework for whole organ recovery and 
allocation.194 Prior to 1984, whether the FDA had authority to 
regulate the marketing of human organs was controversial.195 Of 
course, some people still go abroad for organ transplantation, 
which avoids United States regulations entirely.196 
[NOTA] (1) provided federal funding for regional federal procurement 
agencies; (2) established a national organ procurement and 
transplantation network (OPTN) to manage the procurement and 
distribution of solid donor organs; (3) mandated funding of transplant-
related medication and surgical transplant procedures by 
Medicaid/Medicare; (4) established a task force to formally study organ 
transplant allocation problems; and (5) specifically prohibited the sale 
of donor organs for transplantation though the ban does not apply to 
blood, sperm or ova. The solid organ donor program is purely 
voluntary, both for living and cadaveric organ transplantation.197 
An interesting question for further research is whether a bioprinted 
organ would be subject to NOTA under the organ transplantation 
rule. 
5. Special Case: Cloneprinting Subject to Higher Scrutiny than 
Cloning 
Since cloning is possible198, cloneprinting would technically be 
possible as well. Because bioprinting body parts is already 
happening, a next step would be bioprinting “fully functional 
                                                
 194 See National Organ Transplant Act, 98 Stat. 2339 (1984). 
 195 See, e.g., Bruce Patsner, Human Organ Transplantation in the U.S. – 
Crossing New Lines?, UNIV. OF HOUSTON HEALTH LAW PERSPECTIVES (Aug. 19, 
2008), http://www.law.uh.edu/healthlaw/perspectives/2008/(BP)%20organ.pdf; 
DAVID K.C. COOPER & ROBERT P. LANZA, XENO: THE PROMISE OF 
TRANSPLANTING ANIMAL ORGANS INTO HUMANS 226 (2000). 
 196 See GOODWIN, BODY PARTS’ BLACK MARKETS, supra note 128. 
 197 Patsner, supra note 195. 
 198  See generally Susanna Hornig Priest, Cloning: A Study in News 
Production, 10 PUB. UNDERSTANDING OF SCI. 59, 59–69 (2001) (discussing thee 
cloning ethical debate and public perception of cloning and the ethnical debate 
surrounding cloning). For example, scientists have successfully cloned a sheep 
(the Dolly sheep) in 2004. See supra note 31 and accompanying texts. 
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human[s]”. 199  Given the fundamental differences between 
bioprinting and cloneprinting, the regulations governing each will 
likewise need to be different.200 
Imagine a future where an individual can simply bioprint 
another clone of herself at home; this is a scary yet exciting vision. 
Theoretically, cloneprinting would simply serve as a quick, easy 
modality of production.201 This comparison assumes that the future 
of bioprinting makes it possible to cloneprint a mammalian or 
human clone.202 
Unlike bioprinting body parts, cloneprinting does not require 
doctors’ assistance before the “products,” i.e., clones, are ready for 
use. Similar to how bioprinting differs from synthetic biology, 
cloneprinting differs from cloning in that cloneprinting moves 
clone production out of the laboratory and into everyone’s home, 
making cloneprinting more accessible than cloning.203 Likewise, 
cloneprinting calls for slightly higher scrutiny than cloning.204 
The U.S. House of Representatives voted whether to ban all 
human cloning, both reproductive and therapeutic, in 1998, 2001, 
2004, and 2007, and prevented all bills from passing.205 Currently, 
there is a 2010 bill in the House of Representatives Energy and 
Commerce Committee with a section banning federal funding for 
human cloning.206 The U.S. has no federal law that bans cloning 
                                                
 199 Lynch, Bioprinting the Pathway to Cloning, supra note 97 (“[T]here has 
been a way found to create functional organs; therefore a scientists ‘logical’ 
second step is creating a fully functioning human!”). 
 200 This Article will only discuss regulating bioprinting but not cloneprinting. 
When cloneprinting becomes real, cloneprinting will be a topic for another 
Article. 
 201 Cf. Desai & Magliocca, Napster, supra note 19, at 1719 (discussing 3D 
printing transforms effect on manufacturing). 
 202 See discussion supra Part II.C. and note 98. 
 203 Cf. Kurutz, supra note 8 (discussing that the 3D printer will soon be a 
common home appliance). 
 204 See discussion supra Part III.B.2 (concluding that bioprinting deserves 
slightly higher scrutiny than synthetic biology). 
 205 Human Cloning, ATLANTIS ONLINE, http://atlantisonline.smfforfree2.com/ 
index.php?topic=26838.0;wap2 (last visited Dec. 17, 2014). 
 206 See H.R. 4808, 111th Cong. (2010). 
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completely,207 as any such laws might raise difficult constitutional 
issues similar to the issues seen in the abortion debate. 208 
Nonetheless, thirteen states have banned reproductive cloning and 
three states prohibit use of public funds for cloning.209 
C. Public Policy Behind Regulating Bioprinting 
As analyzed above,210 from the lowest to the highest scrutiny, 
the scrutiny order should be: (1) 3D printing, (2) synthetic biology, 
(3) bioprinting, (4) stem cell research, (5) organ transplantation, 
and in the special case of cloneprinting, (6) cloning would be less 
scrutinized than (7) cloneprinting.211 Given that U.S. biotechnology 
policy “adopts a precautionary approach when it comes to stem 
cells and cloning,”212 a precautionary regulation serves as a good 
starting point. 
1. A “Relaxed” Federal Standard 
Regulating bioprinting needs a standard rather than a rule.213 
Assuming a 3D printer and bioprinter use the same hardware, 
                                                
 207  Cloning: Frequently Asked Questions, NPR, http://www.npr.org/news/ 
specials/cloning/faq_blanknav.html (last visited Aug. 14, 2015) (“Is human 
cloning banned in the United States? In the United States, there are no federal 
laws specifically regarding human cloning.”). 
 208 See, e.g., Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells, and 
Cloning, 31 FLA. ST. U. L. REV. 101, 114–35 (2003).	
 209  See Human Cloning Laws, NAT’L CONF. OF STATE LEGISLATURES, 
http://www.ncsl.org/research/health/human-cloning-laws.aspx (last visited Dec. 
17, 2014). 
 210 See discussion supra Part III.B. 
 211 See also Murphy & Atala, supra note 91, at 773–85. 
 212  Adam D. Sheingate, Promotion Versus Precaution: The Evolution of 
Biotechnology Policy in the United States, 36 BRIT. J. POL. SCI. 243, 243 (2006). 
 213  See generally Russell B. Korobkin, Behavioral Analysis and Legal 
Reform: Rules vs. Standards Revisited, 79 OR. L. REV. 23, 33 (2000) [hereinafter 
Korobkin, Rules vs. Standards]; Louis Kaplow, Rule vs. Standard: An Economic 
Analysis, 42 DUKE L.J. 557, 611–16 (1992) (comparing the differences between 
using a rule and a standard in term of cost). A standard depends on the facts and 
applies on a case-by-case basis whereas a rule clearly lays out what qualifies and 
what does not without leaving much ambiguity left. 
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almost every household would have access to such hardware.214 
The upside of having a rule for regulating bioprinting is that given 
the sheer volume of access to bioprinters, regulating bioprinting 
needs consistency, favoring a strict rule rather than evaluating on a 
case-by-case basis via a broad standard.215 However, the downside 
for having a rule for regulating bioprinting is that bioprinting’s 
wide range of uses216 makes it hard to come up with “one rule [that] 
fits all.”217 
Congress needs to regulate bioprinting at a federal level for 
consistency. If Congress leaves bioprinting regulation up to the 
states, bioprinting regulations would likely vary across the country. 
Furthermore, an individual can “work around” the regulations in 
any state by simply crossing the restricted state’s border to get 
bioprinted “products” in a non-restricted state.218 Congress may 
find a constitutional basis to regulate bioprinting through its 
inherent power to regulate interstate commerce through the 
Commerce Clause—after all, bioprinted products would likely 
either travel through interstate commerce, utilize the 
instrumentality of commerce, or have a cumulative effect on 
interstate commerce.219 
Bioprinting regulations need to be “relaxed” to avoid creation 
of a grey or black market for synthetic human body parts.220 Strict 
                                                
 214 Cf. Kurutz, supra note 8 (discussing that 3D printer will soon be a common 
home appliance). 
 215 See Korobkin, Rules vs. Standards, supra note 213. 
 216 See discussion supra Part II.C. 
 217 Cf. Mark Hellowell, One Rule Fits All?, THE LAWYER (June 2, 2002), 
http://www.thelawyer.com/one-rule-fits-all/97205.article. 
 218  Cf. Barry Friedman & Genevieve Lakier, “To Regulate,” Not “To 
Prohibit”: Limiting the Commerce Power, 2012 SUP. CT. REV. 255, 258–59 
(2012) (questioning whether the Commerce Clause, properly understood, 
“includes the power not only to . . . ‘protect’ interstate markets but also to 
‘eradicate’ them”). 
 219 See U.S. CONST. art. I, § 8, cl. 3 (stating that Congress shall have power 
“[t]o regulate Commerce with foreign Nations, and among the several States, 
and with the Indian Tribes”). 
 220  For a discussion of grey market, see generally John J. McNamara, 
Attention Gray Market Shoppers: K Mart Corp. v. Cartier, Inc. Fails to Clarify 	
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bioprinting regulations would most likely create a grey/black 
market for synthetic human body parts (and possibly clones).221 
Conversely, there would be no point in the existence of a grey or 
black market if bioprinting regulations were “relaxed.” 
2. Positive Public Perception 
The public perception of bioprinting is generally positive: the 
public is excited about bioprinting and its possibilities. 222 
Unfortunately, because the public is less tolerant of risks,223 there 
have been some concerns about the ethics of cloneprinting, which 
presumably carries the same ethical concerns as cloning.224 Further, 
religious groups that fundamentally oppose some aspects of 
science and technology will have even greater opposition to 
bioprinting, given what bioprinting can do.225 
Ideally, society would most likely want to avoid the scenario 
where only a few individuals gain economic benefits from 
bioprinting while the rest of society pays for bioprinting’s 
extremely high cost. Still, society may want to incentivize 
individuals who invent and improve bioprinting by allowing them 
                                                                                                         
the Clouded Area of Gray Market Goods, 38 CATH. U. L. REV. 933, 938–39 
(1989) (“The gray market appears to benefit consumers by offering brand name 
goods at reduced prices. Gray market goods, however, are often of lower quality 
than goods sold by authorized distributors. In many cases, gray market goods are 
subject to different production standards than goods marketed by authorized 
distributors, thus giving rise to inferior and even unsafe products.”) 
 221 Cf. GOODWIN, BODY PARTS’ BLACK MARKETS, supra note 128, at 7 
(discussing the black market which stemmed from the strict regulations of organ 
transplantation). 
 222 See, e.g., TED talk: Growing New Organs, supra note 13; TED talk: 
Printing Human Kidney, supra note 14. 
 223  See, e.g., Dirk Scheer & Ortwin Renn. Public Perception of 
Geoengineering and Its Consequences for Public Debate, 125 CLIMATIC 
CHANGE 305, 305 (2014) (“people seem to cautiously support research but 
oppose deployment while attitude formation depends on personal values and 
belief systems”). 
 224 See, e.g., Andrews, Right to Clone?, supra note 32; Katz, The Clonal 
Child, supra note 32; Robertson, Human Cloning, supra note 32; Warrington, 
Reproductive Cloning, supra note 32. 
 225 See discussion supra Part II.C. 
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to recoup their research and development (“R&D”) investment.226 
This rationale parallels with the creation of Intellectual Property 
rights.227 Conversely, the government can subsidize R&D cost with 
taxpayers’ money, but research dependent on government funding 
would likely lead to a slower growth rate than privately funded 
research.228 
3. Potentially Significant Benefits vs. Very Low Risks 
Bioprinting carries potentially significant benefits and very low 
risks. Overall, bioprinting is a big step for scientific and 
technological progression. Bioprinting benefits society at large by 
providing spare body parts, thereby extending or even saving 
lives. 229  Furthermore, bioprinting could be a step towards 
immortality, where an aged human would replace old tissues with 
new bioprinted tissues.230 Although using bioprinted body parts 
comes with a few inherent risks, such as malfunction or complete 
                                                
 226 Cf. Lila Feisee, Are Biotechnology Patents Important? Yes!, 1 PTO TODAY 
9, 9 (2000) (“[b]iotechnology is one of the most research intensive and 
innovative industries in the global economy today”). 
 227 See generally Edmund W. Kitch, The Nature and Function of the Patent 
System, 20 J.L. & ECON. 265, 275–80 (1977). 
 228 Simply because the private industry has more money to fund research 
compared to the government. See Daniel J. Howard & Frank N. Laird, The New 
Normal in Funding University Science, 30 ISSUES IN SCIENCE & TECHNOLOGY 
no. 1 (2013), http://issues.org/30-1/the-new-normal-in-funding-university-
science/ [hereinafter Howard & Laird, Funding]. 
 229 Although currently a purely scientific fictional concept, providing clones 
could also theoretically save lives by a transfer of one’s memory onto his/her 
replacement clone. The concept of saving lives via bioprinting could open many 
possibilities, for example, bioprinting could theoretically make criminals more 
difficult to apprehend, because they could “escape” into a replacement clone 
(perpetually). Most recently, the movie Self/less portrays this concept of 
criminals “shedding their old bodies” by moving their conscious minds into new 
body hosts. See SELF/LESS (Endgame Entertainment & Entertainment 2015). 
 230 See, e.g., Varkey & Atala, supra note 105, at 291 (2015) (discussing using 
bioprinting “to replace diseased and injured tissue,” “to fight the negative 
consequences of aging,” and “to extend human lifespan”). 
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failure, 231  insurance companies or manufacturer warranties can 
alleviate some of these concerns.232 
Cloneprinting more mammals, especially extinct mammals, 
could drastically affect ecology233 because cloneprinting would 
likely disrupt Darwin’s “survival of the fittest” theory. Some view 
this disruption as a risk while others view it as a benefit, depending 
on whether one is animal-friendly or environment-friendly.234 
Another benefit of bioprinting organs from stem cell sources is 
that the process can be repeated indefinitely, whereas, there is a 
limit to how many organs are available for harvest from living 
humans. This is relevant due to the current shortage of organs for 
transplant. Allowing the bioprinting of functional organs would 
likely solve the organ shortage. This is a clear improvement for 
organ transplantation, assuming no complications arise. 
Furthermore, bioprinting could add backup organs for 
transplantation when mishaps occur in the operation room. 
On a macro level, the most visible advantage of bioprinting is 
that it will replenish the low supply of organ transplantation, thus, 
saving more lives. Bioprinting would also help people achieve 
better health and lengthen human lives by replacing aging organs 
with new ones.235 The improved health that bioprinting would 
achieve could result in a lower workload for physicians, who 
would have fewer sick patients to see. This in turn would likely 
free up physicians’ time from treatment so they could devote their 
                                                
 231  See supra Part III.A.4 (discussing that bioprinted body parts can 
malfunction or completely fail). 
 232 See, e.g., William K. Jones, Product Defects Causing Commercial Loss: 
The Ascendancy of Contract over Tort, 44 U. MIAMI L. REV. 731 (1990). 
 233 See, e.g., Roast, supra note 98 (“Bringing back animals that have gone 
extinct (albeit locally) might just influence ecosystems of the future.”). 
 234 Animal-friendly people would want more animals whereas environment-
friendly people would not want more (or too many) animals affecting the 
balance of the current ecology. Cf. Allen Pursell et al., Too Many Deer: A 
Bigger Threat to Eastern Forests than Climate Change?, COOL GREEN SCI 
(Aug. 22, 2013), http://blog.nature.org/science/2013/08/22/too-many-deer/. 
 235 See, e.g., Lawrence O. Gostin & Anna Garsia, Governing for Health As the 
World Grows Older: Healthy Lifespans in Aging Societies, 22 ELDER L.J. 111–
12 (2014). 
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time to other research areas, thus, preserving healthcare resources 
overall.236 On the micro level, there might be financial issues 
associated with bioprinted organ affordability. 
Further, bioprinting would likely have positive effects on 
society. As a result of the health benefits that bioprinting offers, 
and the lives it saves, there would likely be more individuals to add 
to the work force, helping the economy overall. This would likely 
encourage more innovation and technological advancement—
resulting in an overall positive feedback loop for society. 
Bioprinting could also fix genetic defects. For example, with 
bioprinting, an individual born with four fingers could print 
another hand with all five fingers as replacement. For another 
example, an individual with mismatched teeth could get a perfect 
teeth replacement instead of getting orthodontic braces. 
The risks of bioprinting are mostly still unknown. For example, 
as discussed above, 237  there is some possibility of bioprinters 
emitting unhealthy air and contributing to environmental 
pollution.238 Furthermore, people might worry about the safety of 
bioprinted products, especially when used in the human body. 
These worries include malfunction incidents and who should bear 
liability for such incidents. 
D. Current Regulatory Framework that Bioprinting Would Likely 
Have to Abide by 
Regulating bioprinting belongs in the grey area between an 
outright ban and no regulation because it could fall under human 
stem cell research regulation, or organ transplantation regulation, 
or both. The human stem cell used for bioprinting ink could fall 
under human stem cell research regulation if it were used for 
research purposes. However, what about commercial applications 
of bioprinting ink using human stem cells—would commericial 
applications also fall under current human stem cell research 
regulations even though it is not for research? Once an organ is 
                                                
 236 See id. 
 237 Supra Part III.A.1.  
 238 See Gilpin, supra note 122. 
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bioprinted and ready for transplantation into a human body, the 
organ transplantation regulations might be triggered. For example, 
medical use of bioprinted tissues or organs in humans for 
therapeutic purposes automatically triggers FDA oversight, or, 
even before that, to perform skin grafting via bioprinting on 
humans, one must apply for the FDA’s permission to carry out 
human trials.239 These unclear situations call for a clear regulation 
specifically for bioprinting. 
IV. WAYS TO REGULATE BIOPRINTING 
This Part explores different ways to regulate bioprinting and 
evaluates them under several criteria: flexibility, speed, political 
feasibility, safety, and promotion of innovation. Section A 
contemplates an outright ban or a ban with research and emergency 
exceptions, whereas Section B discusses self-regulation. Section C 
explores some other regulatory ideas: (1) subjecting to approval by 
different authorities, such as the legislative branch, the judicial 
branch and/or the medical profession or (2) regulating individual’s 
access to blueprints, to raw sources, or to the bioprinter. 
It is important to establish criteria to determine when a 
regulatory framework constitutes a “good” outcome. This will 
make it possible to compare different approaches and how they 
achieve these outcomes. This Article compares the different 
approaches in flexibility, speed, political feasibility, safety, and 
promotion of innovation.240 
                                                
 239 Edwards, supra note 101. 
 240 Flexibility describes how broadly a regulation could apply to different 
situations. Speed describes how quickly a regulation could resolve various cases 
and controversies arising from the technology in question. Political feasibility 
describes how likely a regulation would be able to pass through Congress and 
the President—in other words, achieving agreement among people with different 
political views. 
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A. Baning Bioprinting 
1. Outright Ban 
As alluded to earlier,241 an outright ban on bioprinting is an 
easy answer to the question of how to regulate bioprinting. 
However, such a ban would halt all research, resulting in no 
progress in this area of science and technology, and prevent the use 
of bioprinting from saving many lives. Although banning 
bioprinting would be the safest option, this approach would be 
inflexible—there would be no wiggle room for bioprinting 
whatsoever. Banning bioprinting represents one extreme end of 
various solutions and would be unlikely to gather political 
feasibility to pass in the federal legislature. Rather than promoting 
innovation, this approach would instead stunt innovation. Thus, an 
outright ban on bioprinting is the most unattractive and unlikely 
solution. 
2. Ban With Research and Emergency Exceptions 
A quick fix to the flaws of an outright ban is to carve out some 
exceptions, such as those for research and emergencies. To 
overcome a halt in the progression of science,242 it makes sense to 
allow a narrow exception for research and experimentation. The 
scope of research could be up for debate: who qualifies to conduct 
the research, what funding sources are available for the research, 
whether private companies could invest in or conduct research, 
who would have oversight and regulatory power over the 
researchers, and other aspects would be debated.243 One approach 
could mirror the research and experimentation exception in patent 
law. Under common law, one incurs no patent infringement 
liability for use that is “for amusement, to satisfy idle curiosity, or 
                                                
 241 See discussion, supra Part I. 
 242 See discussion, supra Part IV.A.1. 
 243  See MEGHAN B. COULEHAN & JONATHAN F. WELLS, Guidelines for 
Responsible Data Management in Scientific Research (2005), available at 
http://ori.hhs.gov/images/ddblock/data.pdf; NICHOLAS H. STENECK, Introduction 
to the Responsible Conduct of Research (2000), available at 
https://www.mtu.edu/research/administration/integrity-
compliance/pdf/rcrintro.pdf. 
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for strictly philosophical inquiry,”244 and a use is not experimental 
if it has “the slightest commercial implication.”245 
To save lives, it makes sense to allow an emergency 
exception.246 Many doctors believe in a “general duty not to let 
people die.” 247 However, there is no legal duty to not let people 
die, absent some special relationship between the parties. 248 
Otherwise, many would be outraged from the immorality of not 
saving patients-in-need249 and watching them die when we have the 
technology to save them.250 Further, UCLA Law Professor Eugene 
Volokh would argue that these patients-in-need have the 
constitutional right to medical self-defense.251 
Like the research exception, the scope of this exception could 
also be up for debate: whether bioprinting should be limited to 
only life-threatening conditions, and how immediate the life-
threatening conditions must be (for example, immediate 
transplantation for lung failure 252  vs. slow death from lung 
                                                
 244 Madey v. Duke University, 307 F.3d 1351, 1362 (Fed. Cir. 2002). 
 245 Embrex v. Service Engineering, 216 F.3d 1343, 1353 (Fed. Cir. 2000) 
(Rader, H., concurring). 
 246 See supra Part IV.A.1. 
 247 See JAMES RACHELS, Killing and Letting Die, in ENCYCLOPEDIA OF ETHICS 
947–50 (Lawrence Becker & Charlotte Becker eds., 2d ed. 2001) [hereinafter 
RACHELS, Letting Die] (discussing the “general duty not to let people die”). 
 248 For a discussion on the law regarding good Samaritans, see generally 
Robert Justin Lipkin, Beyond Good Samaritans and Moral Monsters: An 
Individualistic Justification of the General Legal Duty to Rescue, 31 UCLA L. 
REV. 252 (1983). 
 249 The “patients-in-need” refer to those patients in life-threatening situations. 
 250 Cf. RACHELS, Letting Die, supra note 247, at 947 (“[Like killing someone,] 
it is also bad to let someone die.”). 
 251 See also Eugene Volokh, Medical Self-Defense, Prohibited Experimental 
Therapies, and Payment for Organs, 120 HARV. L. REV. 1813, 1845–46 (2007) 
(arguing for the constitutional right of medical self-defense to use “experimental 
drug therapies for the terminally ill or market-based solutions to the organ 
shortage.”). 
 252  See, e.g., Jonathan E. Spahr et al., Lung Transplantation for Cystic 
Fibrosis: Current Concepts and One Center’s Experience, 6 J. CYSTIC FIBROSIS 
334, 334–50 (2007). 
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cancer).253 At the very least, people with imminent life-threatening 
conditions should be allowed to use bioprinted products. 
The exceptions make this approach seem more morally 
reasonable than an outright ban, and it is still a relatively safe 
option. However, this approach is not flexible either. Unlike the 
outright ban discussed above, it would be more politically feasible 
to pass a law that banned bioprinting while allowing for 
exceptions. This approach would allow some innovation in the 
research realm, but not much in the commercial application. 
B. Self-Regulation 
On the opposite side of the regulation spectrum to an outright 
ban would be no regulation whatsoever, i.e., allowing citizens to 
self-regulate. 254  Law and economics theory as well as anti-
paternalism255 support the self-regulation proposal: no regulations 
would mean that the government depends on the market to sort 
itself out and puts all trust to each individual, assuming that the 
individual would do the “right” thing.256 The government can still 
offer a supportive role through education and relaying safety 
information to the public.257 Because bioprinting bears very low 
risks,258 this proposal might be suitable. 
                                                
 253 See Darrell Spurlock, Jr., Signs of Death for End Stage Lung Cancer, LIVE 
STRONG (Mar. 7, 2011), http://www.livestrong.com/article/50668-signs-death-
end-stage-lung/. 
 254  See OECD REPORT, ALTERNATIVES TO TRADITIONAL REGULATION 6 
(2005). 
 255 For a discussion on law and economic theory and anti-paternalism, see 
generally Christine Jolls et al., A Behavioral Approach to Law and Economics, 
50 STAN. L. REV. 1471, 1541 (1998) (“In its normative orientation, conventional 
law and economics is often strongly antipaternalistic. . . .[B]ounded rationality 
pushes toward a sort of anti-antipaternalism—a skepticism about 
antipaternalism, but not an affirmative defense of paternalism.”). But see 
Jonathan Klick & Gregory Mitchell, Government Regulation of Irrationality: 
Moral and Cognitive Hazards, 90 MINN. L. REV. 1620, 1626 (2006) 
(“paternalistic interventions may exacerbate irrational tendencies by creating 
moral and cognitive hazards”). 
 256 Id. 
 257 See OECD REPORT, supra note 254, at 7. 
 258 See supra Part III.B.3. 
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However, this view implies completely open access to 
bioprinting technology, resulting in no recoupment in R&D cost 
investments for inventors. 259 Alternatively, the government can 
subsidize R&D costs with taxpayers’ money, but research 
dependent only on government funding would most likely lead to a 
slower growth rate than privately funded research.260 In the end, 
self-regulation may be slightly better than an outright ban,261 but it 
is still an unattractive solution. 
This approach is the most flexible, but the least safe of all 
options. This extreme opposite to an outright bad would be 
unlikely to gather political feasibility as well, because some would 
support it while others would not. In fact, no passage of law is 
needed because there is no regulation. However, this approach 
would promote innovation at full speed, in both the research and 
commercial realms. 
C. Other Possible Regulations 
The happy medium between a ban and self-regulation is to 
enact a moderate amount of regulations. Such regulations should 
derive from the synthesized rationales behind regulating 
bioprinting.262 This paternalistic approach263 could explore different 
parties available for oversight, or restrict access to different 
bioprinting ingredients. 
1. Granting Intellectual Property Rights on Bioprinting 
Technology 
One way to incentivize innovation and investment in R&D is to 
allow inventors to recoup those investments by granting IP rights 
to those inventors. 264  Lila Feisee 265  argues that patenting 
biotechnology is important: 
                                                
 259 See id. 
 260 See Howard & Laird, supra note 228. 
 261 See supra Part IV.B. 
 262 See supra Part III.B. 
 263 See generally SARAH CONLY, AGAINST AUTONOMY: JUSTIFYING COERCIVE 
PATERNALISM (2012) (discussing and defending paternalism). 
 264 See Kitch, supra note 227, at 275–80. 
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Biotechnology patents allow for the dissemination of potentially 
valuable scientific information. The availability of the information 
disclosed in biotechnology patents enables others in the field of science 
to build on earlier discoveries. Not only can other researchers use the 
information in a patent, but by disclosing cutting edge scientific 
information, the patent system avoids expensive duplication of research 
efforts. It is only with the patenting of biotechnology that some 
companies, particularly small companies, can raise capital to bring 
beneficial products to the market place or fund further research. In 
addition, this capital provides jobs that represent an immediate public 
benefit independent of the technological benefits. Continuing 
employment opportunities represent a national resource for the future 
because they encourage the youth of today to become the scientists and 
inventors of tomorrow. Thus, the patent system not only fosters 
benefits to our society today, but ensures our future ability to innovate 
and grow.266 
Unfortunately, granting IP rights for bioprinting will drive up the 
cost to bioprint (with a portion going towards paying for inventors’ 
IP rights), resulting in a longer time before bioprinting can become 
more affordable and available to everyone.267 Further, granting 
bioprinting patents can be complicated,268 e.g., the USPTO may 
grant a patent for a method of printing a lung but not for a lung 
itself because lungs are “products of nature”269 found in every 
                                                                                                         
 265 Lila Feisee is the Vice President of International Affairs for Biotechnology 
Industry Organization and was a Supervisory Patent Examiner for the 
Biotechnology group at the USPTO. Lila Feisee, LINKEDIN, 
https://www.linkedin.com/in/lilafeisee (last visited Nov. 4, 2014). 
 266 Feisee, supra note 226, at 9–12. 
 267 See also MICHELE BOLDRIN & DAVID K. LEVINE, AGAINST INTELLECTUAL 
MONOPOLY (2010) (arguing that license fees, regulations and patents are now so 
misused that they drive up the creation cost and slow down the diffusion rate of 
new ideas). 
 268 This is a common issue faced by inventors: the composition of matter is 
not patentable but the process for making that composition of matter is novel 
and patentable. Also, there are so-called “product-by-process” claims that allow 
an inventor to claim a product created by a specific process, provided that 
product is different from the prior art in some way. 
 269 See also Ass’n for Molecular Pathology v. Myriad, 133 S. Ct. 2107, 2116–
17 (2013) (holding that naturally occurring DNA segments precludes patent 
eligibility). See generally 35 U.S.C. § 101 (2012) (discussing patentable subject 
matters). 
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human. Nonetheless, this is the patent examiners’ job, and the 
USPTO can take care of this intricacy.270 
As stated above,271 the government can alternatively subsidize 
R&D costs with taxpayers’ money, but research dependent only on 
government funding would most likely slow science progression.272 
Put simply, privately funded research often has deeper pockets 
than government-funded research. Thus, steady science 
progression demands granting IP rights for bioprinting technology. 
2. Prohibiting Sales 
It is important to prohibit sales of bioprinted body parts.273 
Fairness and equality favor accessibility for everyone and ideally 
we do not want a few business-minded people to take advantage of 
this new technology for their own self-serving commercial 
interests.274 Otherwise, such commodification of bioprinted body 
parts would undermine bodily integrity and science’s credibility.275 
This is especially relevant now given that public trust in science 
has been declining276 (partially due to technophobia277 and many 
religious influences278). 
                                                
 270 See Brian Fung, Inside the Stressed-out, Time-Crunched Patent Examiner 
Workforce, WASH. POST, July 31, 2014, http://www.washingtonpost.com/ 
blogs/the-switch/wp/2014/07/31/inside-the-stressed-out-time-crunched-patent-
examiner-workforce/. At the USPTO, a patent examiner’s job is to decide which 
invention is patentable and to grant patents. For a more thorough discussion on 
patenting bioprinting, see generally Tran, Patenting Bioprinting, supra note 94. 
 271 See supra Part IV.C.1. 
 272 See Howard & Laird, supra note 228. 
 273 See generally GOODWIN, BODY PARTS BLACK MARKETS, supra note 128 
(discussing the black market for organs). 
 274 Cf. YVONNE DENIER, EFFICIENCY, JUSTICE AND CARE: PHILOSOPHICAL 
REFLECTIONS ON SCARCITY IN HEALTH CARE 76–79 (2007) (discussing the right 
to universal healthcare). 
 275 See Stephen Wilkinson & Eve Garrard, Bodily Integrity and the Sale of 
Human Organs, 22 J. MED. ETHICS 334, 334–39 (1996). But see Stephen 
Wilkinson, Commodification Arguments for the Legal Prohibition of Organ 
Sale, 8 HEALTH CARE ANALYSIS 189, 189–201 (2000). 
 276  See Carolyn Abbot, Bridging the Gap – Non-state Actors and the 
Challenges of Regulating New Technology, 39 J.L. SOC’Y 329, 351–58 (2012) 
(discussing the challenges facing the public trust in “non-state actors” and 
emerging technologies). 
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Unfortunately, these businessmen can simply “work around” 
such prohibition of bona fide sales 279  by donating bioprinted 
“products” and receiving the money as a gift. 280  But if the 
government decided to prohibit both sales and donation, 
consumers would have no way to access bioprinted products.281 
Therefore, it makes sense to prohibit sales of bioprinted products. 
3. Subject to Approval 
One perspective from which to think about regulating 
bioprinting is to subject bioprinting uses to approval,282 but it begs 
the question: who should regulate bioprinting? Some available 
parties for oversight are administrative agencies, courts, and 
medical professionals.283 
The legislature can either establish and delegate to a new 
agency284 dedicated solely to regulating bioprinting or depend on 
                                                                                                         
 277 Technophobia is a fear of emerging technology. See generally Adam 
Thierer, The Internet of Things and Wearable Technology: Addressing Privacy 
and Security Concerns without Derailing Innovation, 21 RICH. J.L. & TECH. 6, 
32 (2015). 
 278 See, e.g., Answers Staff, Religious Beliefs on Selling Organs, ANSWERS, 
http://religion.answers.com/controversy/religious-beliefs-on-selling-organs (last 
visited Oct. 3, 2015). 
 279  See, e.g., U.S. CUSTOMS AND BORDER PROTECTION, WHAT EVERY 
MEMBER OF THE TRADE COMMUNITY SHOULD KNOW ABOUT: BONA FIDE SALES 
& SALES FOR EXPORTATION TO THE UNITED STATES (2005), available at 
http://www.cbp.gov/sites/default/files/documents/icp010r2_3.pdf (discussing 
bona fide sales and the factors determinative of bona fide sales). 
 280 Cf. Donald B. Tobin, Political Advocacy and Taxable Entities: Are They 
the Next “Loophole”?, 6 FIRST AMEND. L. REV. 41, 90–93 (2007) (discussing 
the “loophole” behind gift tax). 
 281 Cf. GOODWIN, BODY PARTS BLACK MARKETS, supra note 128 (discussing 
the case of organ transplantation, where organ sales were prohibited and only 
donations were allowed). 
 282 Another underlying question is whether such approval is on a case-by-case 
basis or differs based on different types of bioprinted products. 
 283 See generally Marcia L. McCormick, Federal Regulation and the Problem 
of Adjudication, 56 ST. LOUIS U. L.J. 39 (2011). 
 284 The U.S. Supreme Court has allowed some delegation of legislative power 
but such delegation must comply with the “intelligible principle” test. See 
Mistretta v. United States, 488 U.S. 361, 372–73 (1989) (citing Am. Power & 
Light Co. v. SEC, 329 U.S. 90, 92 (1946)) (deeming a delegation of legislative 	
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existing agencies285 such as the Department of Health & Human 
Services (HHS)286 or the Food and Drug Administration (FDA). In 
order to delegate, the legislature must take care of administrative 
law issues, such as whether the new agency or existing agencies 
have authority to regulate bioprinting.287 
Inherent in the judicial power from the Constitution’s “Case or 
Controversy” Clause,288 courts may be available to approve the 
uses of bioprinting’s “products.”289 However, it might not make 
much sense to exhaust judicial resources for oversight when courts 
would most likely be busy with adjudicating disputes as well.290 
Alternatives for subsequent disputes may be subject to Alternative 
                                                                                                         
power “constitutionally sufficient if Congress clearly delineates the general 
policy, the public agency which is to apply it, and the boundaries of this 
delegated authority”); Wayman v. Southard, 23 U.S. 1, 1–2 (1825). 
 285 See also Leili Fatehi et al., Recommendations for Nanomedicine Human 
Subjects Research Oversight: An Evolutionary Approach for an Emerging Field, 
40 J. LAW MED. ETHICS 716, 716 (2012) [hereinafter Fatehi, HSR Oversight] 
(explaining that human subjects research on nanomedicine interventions is 
subject to many oversight rules and regulations.); Susan M. Wolf & Cortney M. 
Jones, Designing Oversight for Nanomedicine Research in Human Subjects: 
Systematic Analysis of Exceptional Oversight for Emerging Technologies, 13 J. 
NANOPARTICLE RES. 1449, 1449 (2011) (“Certain types of human subjects 
research, however, have provoked creation of additional mechanisms and rules 
beyond the [DHHS] Common Rule and [FDA] equivalent.”). 
 286  For background on the HHS, see generally About HHS, HHS, 
http://www.hhs.gov/about/ (last visited Nov. 5, 2014) (“[The HHS] protect[s] 
the health of all Americans. The HHS[,] provid[es] for effective health and 
human services and fostering advances in medicine, public health, and social 
services.”).  
 287 Cf. Whitman v. Am. Trucking Ass’ns, 531 U.S. 457, 485–86 (2001) 
(deciding issue of the Environmental Protection Agency’s (EPA) administrative 
authority); Am. Lung Ass’n v. EPA, 134 F.3d 388, 392 (D.C. Cir. 1998); Marc 
Landy, EPA and Nanotechnology: The Need for a Grand Bargain?, in 
GOVERNING UNCERTAINTY: ENVIRONMENTAL REGULATION IN THE AGE OF 
NANOTECHNOLOGY 80–101 (Christopher J. Bosso ed., 2010) (discussing the 
EPA’s institutional capacity to regulate nanotechnology). 
 288 See U.S. CONST. art. III, § 2, cl. 1. 
 289 For example, there may be a controversy between an individual and 
another administrative agency on the issue of whether an individual can use 
bioprinting’s “product.” 
 290 See McCormick, supra note 283, at 62. 
170 N.C. J.L. & TECH. [VOL. 17: 123 
Dispute Resolution (ADR), such as mediation or arbitration.291 
Because courts are cloaked with the shroud of impartiality and 
judicial independence,292 they may not want to be involved in, and 
face being blamed for, erroneous bioprinting approval. Although 
an option to appeal293 may mitigate this, this proposal still seems 
unattractive. 
The legislature can also defer to medical professionals’ 
judgment. 294  Some may say that regulating bioprinting is the 
legislators’ job, not medical professionals’ job.295 Regardless, this 
makes the most sense for three reasons: (1) unlike medical 
professionals, the public and the legislators lack the requisite 
scientific and health knowledge;296 (2) the general public trusts 
                                                
 291 See generally Rachel Jacobs, Should Mediation Trigger Arbitration in 
Multi-Step Alternative Dispute Resolution Clauses?, 15 AM. REV. INT’L ARB. 
161 (2004) (discussing alternative dispute resolution, mediation, and 
arbitration). 
 292 See also Maria Dakolias & Kim Thachuk, The Problem with Eradicating 
Corruption in the Judiciary, in THE CHALLENGE OF CHANGE FOR JUDICIAL 
SYSTEMS 140 (Marco Fabri & Philip M. Langebroek eds., 2000) (“Judicial 
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 294  See Nadia N. Sawicki, Doctors, Discipline, and the Death Penalty: 
Professional Implications of Safe Harbor Policies, 27 YALE L. & POL’Y REV. 
107, 166 (2008) (“[L]egal delegation of regulatory power to the medical 
profession itself engenders trust in the profession.”). 
 295 But cf. id.  
 296 See, e.g., Joseph Chien, Between Scientific Discourse and Lay Knowledge: 
Understanding the Non-Medical Use of Stimulants, 22 S. CAL. REV. L. & SOC. 
JUST. 185, 193–97 (2013) (discussing the public’s lack of medical knowledge in 
non-medical uses of stimulants); Clifford F. Hawkins, Writing and Speaking in 
Medicine. Writing the MD Thesis, 2 BRIT. MED. J. 1121, 1121–24 (1976) 
(discussing the medical professionals possessing scientific and health 
knowledge); David Ropeik, The Perception Gap: Recognizing and Managing 
the Risks that Arise when We Get Risk Wrong, 50 FOOD & CHEM. TOXICOLOGY 
1222, 1222–25 (2012) (discussing the public’s simplistic “perception gap” of 
risks based on the media); Scheer & Renn, supra note 223, at 305 (“Existing 
studies on geoengineering perceptions show low levels of awareness and a lack 
of knowledge.”). 
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medical professionals for health-related issues;297 and (3) medical 
professionals are in the best position to assess an individual’s 
health needs298 without allowing room for abuses of bioprinting 
technology. For example, doctors can approve bioprinting uses 
similar to how they approve medical marijuana uses—on a need-
based basis.299 If not subject to medical professionals’ judgment for 
a need-based basis, then why would an individual want extra spare 
parts if she does not need them? Perhaps to hoard these spare 
parts,300 just in case, but such a hoarder’s mindset does not make 
much economic sense.301 Thus, deferring to medical professionals’ 
judgment might work, but it should only be based on need. 
One may ask how deferring to medical professionals’ judgment 
differs from the research exception, as discussed above.302  Both 
are similar in some ways, but deferring to medical professionals’ 
judgment is more expansive and also covers the emergency 
exception discussed above.303 Further, the emergency exception 
assumes doctors would always do the right thing, and not let 
individuals die, whereas this may not always hold true.304 Congress 
                                                
 297 But see Abbot, supra note 276, at 351–58 (discussing the challenges facing 
the public trust in “non-state actors” and emerging technologies). 
 298 See generally INSTITUTE OF MEDICINE, CONFLICT OF INTEREST IN MEDICAL 
RESEARCH, EDUCATION, AND PRACTICE (Bernard Lo & Marilyn J. Field eds, 
2009) (discussing the expertise medical professionals have when it comes to 
health). 
 299 See generally Michael Berkey, Mary Jane’s New Dance: The Medical 
Marijuana Legal Tango, 9 CARDOZO PUB. L. POL’Y & ETHICS J. 417 (2011) 
(discussing the legality of medical marijuana). 
 300 This assumes an individual cannot donate or sell bioprinted “products,” 
given the prohibition against sales and donation of bioprinted “products.” See 
supra notes 273–81 and accompanying text. 
 301 See Keith Sharfman, The Law and Economics of Hoarding, 19 LOY. 
CONSUMER L. REV. 179, 183–90 (2007). 
 302 See supra notes 235–38 and accompanying text. 
 303 See Ariel R. Schwartz, Doubtful Duty: Physicians’ Legal Obligation to 
Treat During an Epidemic, 60 STAN. L. REV. 657, 668–81 (2007) (discussing 
physicians’ duty in absence of an “emergency”). 
 304 But see Rachels, Letting Die, supra note 247, at 947–50 (discussing the 
“general duty not to let people die”). For instance, Congress would be deferring 
to a doctor, wherein it could be the very doctor that would not “do the right 
thing” and would in fact “let the individuals die.” See id. 
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can avoid the wrong side of this assumption by both deferring to 
medical professionals’ judgment and including the emergency 
exception.305 
4. Regulating Individuals’ Access 
Another perspective to think about regulating bioprinting is to 
regulate individuals’ access to the bioprinting ingredients—
bioprinters, raw sources, or blueprints. 
If 3D printing and bioprinting use the same printer, then 
regulating an individual’s access to the printer becomes moot 
unless the 3D printer is also regulated—a very unlikely solution 
because 3D printers are already widely available for sale. If 3D 
printing and bioprinting use different printers, bioprinters can be 
regulated by only granting access to the bioprinter to those 
trustworthy ones who regulate the bioprinter’s access by approval 
as discussed above.306 
The private sector would likely provide the raw materials,307 
which can be regulated by subjecting them to approval by an 
administrative agency, as discussed above. 308  Regulating 
bioprinting’s raw materials can be analogous to requiring approval 
for access to dangerous chemicals by the Environmental Protection 
Agency (EPA).309 However, although bioprinting’s basic building 
blocks are relatively small in size,310 one bioprinted “product” still 
                                                
 305 See supra notes 235–38 and accompanying text. 
 306 See supra notes 273–94 and accompanying text. 
 307  See VIRGINIA HAUFLER, A PUBLIC ROLE FOR THE PRIVATE SECTOR: 
INDUSTRY SELF-REGULATION IN A GLOBAL ECONOMY 105–22 (Carnegie 
Endowment for Int’l Peace 2001) (discussing the role of businesses in the 
modern world). 
 308 See supra notes 273–77 and accompanying text. 
 309  See Toxic Substances Control Act, 15 U.S.C. §§ 2601–29 (2012) 
(requiring the EPA to compile, keep current, and publish a list of each chemical 
substance manufactured or processed in the U.S.). See generally About EPA, 
EPA, http://www2.epa.gov/aboutepa/our-mission-and-what-we-do (last visited 
Nov. 9, 2014) (stating that its mission is “to protect human health and the 
environment”). 
 310 See Varkey & Atala, supra note 105, at 275–78 (discussing how each 
building block for bioprinting is composed of cells or tissue). 
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needs a substantial amount of “raw materials” 311  to print, 
potentially making keeping track of the sources difficult. 
Regulating blueprints can be tricky because it depends on 
whether the blueprints are genetic-dependent.312 If they are not 
genetic-dependent, blueprint files should have restricted access to 
avoid easy sharing and copying. One possible solution is to 
regulate blueprint files from the cloud. Because individuals will 
most likely access blueprints from the cloud,313 such blueprints 
could be regulated through licensing, such as through a one-time 
end user license agreement.314 
Conversely, if the blueprints are genetic-dependent,315 the next 
question is how does genetic-dependent bioprinting work—most 
likely a lung blueprint only needs last-step input of an individual’s 
genetic material rather than the beginning. If so, regulating such 
blueprints can be analyzed similar to a non-genetic-dependent 
blueprint. If a blueprint needs an individual’s genetic information 
in the beginning, regulating access to the blueprint becomes more 
complicated. For example, can blueprints be subject to 
                                                
 311 For a discussion of bioprinting’s “raw materials,” see generally supra 
notes 86–113 and accompanying text. 
 312 This means a blueprint depends on each individual’s genetic information. 
 313  See David A. Couillard, Defogging the Cloud: Applying Fourth 
Amendment Principles to Evolving Privacy Expectations in Cloud Computing, 
93 MINN. L. REV. 2205, 2216 (2009) (stating that “[c]loud platforms give users 
‘anywhere access’ to applications and data stored on the Internet”); see also 
William Jeremy Robison, Free at What Cost?: Cloud Computing Privacy Under 
the Stored Communications Act, 98 GEO. L.J. 1195, 1199–204 (2010) 
(discussing the era of cloud computing). 
 314  See generally Justin M. Ackerman, An Online Gamer’s Manifesto: 
Recognizing Virtual Property Rights by Replacing End User Licensing 
Agreements in Virtual Worlds, 6 PHOENIX L. REV. 137 (2012) (discussing end 
user licensing agreements). 
 315 See Rob Stein, Combining The DNA Of Three People Raises Ethical 
Questions, NPR (Nov. 10, 2014 3:03 AM), http://www.npr.org/blogs/ 
health/2014/11/10/360342623/combining-the-dna-of-three-people-raises-ethical-
questions?utm_source=facebook.com&utm_medium=social&utm_campaign=np
r&utm_term=nprnews&utm_content=2035 (discussing the ethical issues of 
DNA transplantation and combining DNA of three people). 
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censorship—without violating the First Amendment 316 —before 
scanning or feeding the bioprinter an individual’s genetic 
information? Answers to this question and other similar 
mechanistic questions would necessarily affect bioprinting 
blueprints’ regulation. 
V. HOW SHOULD WE REGULATE BIOPRINTING? 
The billion-dollar question317 is how to regulate bioprinting, 
given the “grey” status of where bioprinting would fall on the 
current regulatory framework of stem cell research and/or organ 
transplantation. 318  After exploring some options for regulating 
bioprinting,319 the extreme ends of no regulation or self-regulation 
seem fairly unattractive and unlikely.320 This Article proposes a 
solution somewhere in the middle, taking into account the 
rationales behind regulating bioprinting. 
A. Joint Efforts of the Legislature and the Medical Professionals 
A worthwhile solution to the problem will likely be a 
combination of different ways to regulate bioprinting. 321  This 
Article proposes that except for research and emergency, 
bioprinting regulation should be a joint effort of a federal 
administrative agency and the medical profession. Specifically, the 
medical professionals should have access to bioprinters whereas 
the administrative agency should regulate access to bioprinting’s 
basic building blocks and blueprints upstream. Further, IP rights on 
                                                
 316 U.S. CONST. amend. I. 
 317 Cf. $100 Billion IP Losses, supra note 168 (discussing the prediction of an 
annual global IP loss of at least $100 billion from 3D printing by 2018). By the 
same token, because bioprinting is a subcategory of 3D printing, bioprinting will 
be another billion-dollar industry that needs regulation. See supra notes 86–113 
and accompanying text. 
 318 See supra notes 1–42, and accompanying text 
 319 See generally supra notes 240–316 and accompanying text. 
 320 See supra notes 240–61 and accompanying text. 
 321 See supra notes 240–53, 273–305 and accompanying text. 
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bioprinting should be allowable but there should be a prohibition 
against sales.322 
The administrative agency should be an existing one rather 
than a new one for a smooth transition—an already-existent 
agency’s infrastructure would save time, money, and “easing” in of 
the new regulations. The HHS would be the most appropriate 
agency to regulate access to bioprinting’s basic building blocks 
and blueprints upstream because the HHS is most familiar with 
handling research and likely emerging technology related to health 
and human services. Furthermore, when issues arise, such 
controversies may be ironed out in the judicial system. 
B. Advantages and Implications 
This proposal takes the “relaxed” stand to allow possibly the 
broadest uses of bioprinting while still regulating access to it and 
avoiding abuses. The advantage of this proposal will also align 
with advantages of using bioprinting itself because this proposal 
facilitates the development and progression of bioprinting. 
1. Allowing Science and Technology to Progress 
This “relaxed” proposal allows for the broadest use of 
bioprinting while still keeping it in check.323 This allows science 
and technology to progress at a steady growth rate without 
hindering it, thus promoting innovation. More science and 
technology advances lead to a positive feedback loop, resulting in 
better bioprinting technology. 
Some people might criticize this proposal as too “relaxed,” but 
this is a compromise between no regulation and a complete ban, as 
explained above. The trade-off is advancement of science and 
technology—some benefits might be worth the risks. 
                                                
 322 For an extensive discussion of this proposal’s application, see generally 
supra notes 240–316 and accompanying text. 
 323 Cf. Thierer, supra note 277 (discussing how keeping emerging technology 
in check stems from people’s fear of emerging technology). 
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2. Bringing Along Many Health-Related Benefits 
This proposal takes the “relaxed” approach to allow the 
broadest uses of bioprinting while still regulating it. It puts trust in 
the medical professionals to exercise their medical judgment.324 
Here, the advantage of this proposal aligns with the advantages of 
using bioprinting, as discussed above: providing individuals with 
better health, lengthening human lives, saving more lives, solving 
the organ shortage, preserving healthcare resources, and benefiting 
the society overall.325 
3D printers provide a method to print objects in a quick and 
easy way. Bioprinters provide an easy method to print organs, 
which has not been accomplished before. This advantage stems 
from 3D printing’s inherent benefits. Allowing relaxed regulation 
on bioprinting will ease the manufacturing and production of 
organs, allowing more organs to be produced. 
C. Defenses Against Conventional Criticisms 
1. “Playing God” 
A common religious criticism to modern biotechnology is the 
“playing God” objection.326 To “play[] God” is to disregard of 
God’s creation, and to alter things that are “natural.””327 
“Playing God” is a widely used criticism that has surfaced in 
“anesthesia against pain, the birth control pill, transplantation 
medicine and diagnosing brain death, stem cell research[,] genetic 
engineering,” and synthetic biology.328 If scientists and doctors 
                                                
 324 Cf. DAVID DESTENO, THE TRUTH ABOUT TRUST: HOW IT DETERMINES 
SUCCESS IN LIFE, LOVE, LEARNING, AND MORE (2014) (discussing the general 
mechanics and benefits of trust). 
 325 See supra notes 229–38 and accompanying text. 
 326 See Peter Dabrock, Playing God? Synthetic Biology as a Theological and 
Ethical Challenge, 3 SYS. & SYNTH. BIOL. 47, 47 (2009) (“Almost every step 
forward in research has provoked vehement protest against the disregarding of 
creation”). 
 327  Id. at 47–54. Cf. Cecil A.J. Coady, Playing God, in HUMAN 
ENHANCEMENT 155–80 (Julian Savulescu & Nick Bostrom eds., 2009) (arguing 
using neuroenhancement is like “playing God”). 
 328 See Dabrock, supra note 326, at 47–48. 
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“play[] God,” they risk offending some religious groups. But if 
they do not “play[] God,” they would not progress and move 
forward with scientific innovations and discoveries, and we would 
not be saving as many lives.329 In this situation, it may be better to 
“play[] God” while keeping ethical considerations in mind.330 
2. Supporting Designer Babies and Undercutting the Cosmetic 
Surgery Industry 
Imagine an individual was born with brown eyes but wanted 
blue eyes, he can print a pair of blue eyes to swap with the brown 
ones he currently has. This raises a problem similar to the 
“designer babies” situation.331 However, the counterargument is 
that bioprinting a body part replacement is not much different than 
getting cosmetic surgery, allowing individuals to receive, for 
example, fake breasts or a rhinoplasty. In fact, the world condones 
cosmetic surgery and people in the United States are the biggest 
consumers of cosmetic surgery. 332  But the cosmetic surgery 
industry itself would oppose a “relaxed” bioprinting regulation 
because bioprinting would likely undercut the cosmetic industry’s 
business. Nonetheless, the cosmetic surgery industry’s loss-of-
business concern should not outweigh bioprinting’s most obvious 
advantage of saving human lives. 
                                                
 329 Some would argue that scientific progression and not playing God are not 
mutually exclusive by carving out what scientific advancement is okay and what 
is not under God’s eyes. But in reality, it is either you “play God” or you do not. 
No one gets to decide what is allowed under God’s eyes—otherwise those few 
who interpret God’s view would control the world of science. 
330 Tran, Patenting Bioprinting, supra note 94. 
 331 See Suter, supra note 124. 
 332 See, e.g., Lizzie Dearden, Top 10 Countries for Cosmetic Surgery Revealed 
as Figures Show Rising Demand for Penis Enlargements and Other Procedures, 
THE INDEPENDENT (July 30, 2014), http://www.independent.co.uk/life-
style/health-and-families/health-news/top-10-countries-for-cosmetic-surgery-
revealed-as-figures-show-industry-is-booming-worldwide-9636861.html (“The 
United States topped the international chart, with almost 4 million people going 
under the knife or needle.”). 
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VI. CONCLUSION 
Bioprinting carries little risks compared to the enormous 
potential benefits of the technology. The billion-dollar question is 
how to regulate bioprinting, given the murky status of where 
bioprinting would fall on the current regulatory framework of stem 
cell research and organ transplantation. The human stem cells used 
for bioprinting ink could fall under human stem cell research 
regulation if used for research purposes, and/or even commercial 
application. Once an organ is bioprinted and ready for 
transplantation into a human body, the organ transplantation 
regulations might be triggered. For example, medical use of 
bioprinted tissues or organs in humans for therapeutic purposes 
automatically triggers FDA oversight, or even before that, to 
perform skin grafting via bioprinting on humans, one must apply 
for FDA’s permission to carry out human trials. 
This proposed bioprinting regulation suggests that, except for 
research and emergency, bioprinting regulation should be a joint 
effort of a federal administrative agency and the medical 
profession. Specifically, medical professionals should have access 
to bioprinters whereas the administrative agency should regulate 
access to bioprinting’s basic building blocks and blueprints 
upstream. Furthermore, IP rights on bioprinting technology should 
be allowable but there should be a prohibition against sales. The 
overseeing administrative agency should be an existing one rather 
than a new one for a smooth transition. The HHS would be most 
appropriate to regulate access to bioprinting’s basic building 
blocks and blueprints upstream. Furthermore, when issues arise, 
such controversies may be ironed out in the judicial system. 
Using this “relaxed” standard allows science and technology to 
progress, and promotes innovation. Furthermore, this proposal 
would likely provide individuals with better health, lengthen 
human lives, save more lives, solve the organ shortage, preserve 
healthcare resources, and benefit society overall. 
 
